Spironolactone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Spironolactone" in English language version.

refsWebsite

Global rank English rank

234nih.gov

4^th place

192doi.org

2^nd place

90web.archive.org

1^st place

86books.google.com

3^rd place

66semanticscholar.org

11^th place

8^th place

8worldcat.org

5^th place

4handle.net

102^nd place

76^th place

4harvard.edu

18^th place

17^th place

3drugs.com

399^th place

333^rd place

2clincalc.com

3,912^th place

2,496^th place

2europa.eu

68^th place

117^th place

2fda.gov

447^th place

338^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1amh.net.au

low place

1lshtm.ac.uk

low place

1wpath.org

low place

1moderntranshormones.com

low place

1medlineplus.gov

1,581^st place

1,299^th place

1fu-berlin.de

3,329^th place

4,598^th place

1losalt.com

low place

1chemspider.com

8,573^rd place

low place

1sgo-iasgo.com

low place

amh.net.au

amhonline.amh.net.au

"Australian Medicines Handbook". amhonline.amh.net.au. Retrieved 12 May 2025.

books.google.com

Loughlin KR, Generali JA (2006). The Guide to Off-label Prescription Drugs: New Uses for FDA-approved Prescription Drugs. Simon and Schuster. pp. 131–. ISBN 978-0-7432-8667-1. Archived from the original on 7 October 2022. Retrieved 6 November 2016.
Clark MA, Harvey RA, Finkel R, Rey JA, Whalen K (15 December 2011). Pharmacology. Lippincott Williams & Wilkins. pp. 286, 337. ISBN 978-1-4511-1314-3. Archived from the original on 7 October 2022. Retrieved 6 November 2016.
Farid NR, Diamanti-Kandarakis E (27 February 2009). Diagnosis and Management of Polycystic Ovary Syndrome. Springer Science & Business Media. pp. 235–. ISBN 978-0-387-09718-3. Archived from the original on 7 October 2022. Retrieved 6 November 2016.
Szasz G, Budvari-Barany Z (19 December 1990). Pharmaceutical Chemistry of Antihypertensive Agents. CRC Press. pp. 91–. ISBN 978-0-8493-4724-5.
McDonagh TA, Gardner RS, Clark AL, Dargie H (14 July 2011). Oxford Textbook of Heart Failure. OUP Oxford. pp. 403–. ISBN 978-0-19-957772-9. Archived from the original on 27 March 2017.
Parkinson A (2001). Biotransformation of Xenobiotics. McGraw-Hill. pp. 137–138, 169, 171, 180, 195, 208. Archived from the original on 7 October 2022. Retrieved 12 August 2018.
Klaassen CD (11 December 2007). Casarett & Doull's Toxicology: The Basic Science of Poisons, Seventh Edition. McGraw Hill Professional. p. 173. ISBN 978-0-07-159351-9. Archived from the original on 7 October 2022. Retrieved 12 August 2018.
Black HR, Elliott W (28 December 2006). Hypertension: A Companion to Braunwald's Heart Disease. Elsevier Health Sciences. pp. 295–. ISBN 978-1-4377-1078-6. Archived from the original on 7 October 2022. Retrieved 12 August 2018.
Maizes V (2015). Integrative Women's Health (2 ed.). Oxford University Press. p. 746. ISBN 978-0-19-021480-7.
Deedwania PC (30 January 2014). Drug & Device Selection in Heart Failure. JP Medical Ltd. pp. 47–. ISBN 978-93-5090-723-8. Archived from the original on 7 October 2022. Retrieved 5 July 2017.
Ottow E, Weinmann H (9 July 2008). Nuclear Receptors As Drug Targets. John Wiley & Sons. p. 410. ISBN 978-3-527-62330-3. Archived from the original on 21 June 2013. Retrieved 28 May 2012.
Wermuth CG (24 July 2008). The Practice of Medicinal Chemistry. Academic Press. p. 34. ISBN 978-0-12-374194-3. Archived from the original on 21 June 2013. Retrieved 27 May 2012.
Sittig M (1988). Pharmaceutical Manufacturing Encyclopedia. William Andrew. p. 1385. ISBN 978-0-8155-1144-1. Archived from the original on 20 June 2013. Retrieved 27 May 2012.
Ronco C, Bellomo R, Kellum JA, Ricci Z (14 December 2017). Critical Care Nephrology E-Book. Elsevier Health Sciences. pp. 371–. ISBN 978-0-323-51199-5. Archived from the original on 7 October 2022. Retrieved 17 August 2018.
Preedy VR (1 January 2012). Handbook of Hair in Health and Disease. Springer Science & Business Media. pp. 132–. ISBN 978-90-8686-728-8. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Shalita AR, Del Rosso JQ, Webster G (21 March 2011). Acne Vulgaris. CRC Press. pp. 33–. ISBN 978-1-61631-009-7. Archived from the original on 9 December 2016.
Zouboulis CC, Katsambas AD, Kligman AM (28 July 2014). Pathogenesis and Treatment of Acne and Rosacea. Springer. pp. 121–. ISBN 978-3-540-69375-8. Archived from the original on 10 December 2016.
Sloane E (2002). Biology of Women. Cengage Learning. pp. 160–. ISBN 978-0-7668-1142-3. Archived from the original on 7 October 2022. Retrieved 5 July 2017.
Hanno PM, Guzzo TJ, Malkowicz SB, Wein AJ (26 January 2014). Penn Clinical Manual of Urology E-Book: Expert Consult - Online. Elsevier Health Sciences. pp. 782–. ISBN 978-0-323-24466-4. Archived from the original on 7 October 2022. Retrieved 5 July 2017.
Harper C (1 August 2007). Intersex. Berg. pp. 123–. ISBN 978-1-84788-339-1. Archived from the original on 7 October 2022. Retrieved 5 July 2017.
Blume-Peytavi U, Whiting DA, Trüeb RM (26 June 2008). Hair Growth and Disorders. Springer Science & Business Media. pp. 161–162. ISBN 978-3-540-46911-7. Archived from the original on 7 October 2022. Retrieved 16 July 2017.
Smith RE (4 April 2013). Medicinal Chemistry – Fusion of Traditional and Western Medicine. Bentham Science Publishers. pp. 306–. ISBN 978-1-60805-149-6. Archived from the original on 29 May 2016.
Ostrzenski A (2002). Gynecology: Integrating Conventional, Complementary, and Natural Alternative Therapy. Lippincott Williams & Wilkins. pp. 86–. ISBN 978-0-7817-2761-7. Archived from the original on 6 October 2022. Retrieved 5 July 2017.
Shelley WB, Shelley ED (2001). Advanced Dermatologic Therapy II. W. B. Saunders. ISBN 978-0-7216-8258-7. Archived from the original on 6 October 2022. Retrieved 2 January 2019.
Balen A, Franks S, Homburg R, Kehoe S (October 2010). Current Management of Polycystic Ovary Syndrome. Cambridge University Press. pp. 132–. ISBN 978-1-906985-41-7. Archived from the original on 6 October 2022. Retrieved 2 January 2019.
Muller NF, Dessing RP (19 June 1998). European Drug Index: European Drug Registrations (Fourth ed.). CRC Press. pp. 44–. ISBN 978-3-7692-2114-5. Archived from the original on 7 October 2022. Retrieved 29 November 2017.
Lee M, Desai A (2007). Gibaldi's Drug Delivery Systems in Pharmaceutical Care. ASHP. pp. 312–. ISBN 978-1-58528-136-7. Archived from the original on 7 October 2022. Retrieved 1 December 2016.
Niazi SK (19 April 2016). Handbook of Pharmaceutical Manufacturing Formulations, Second Edition: Volume One, Compressed Solid Products. CRC Press. pp. 470–. ISBN 978-1-4200-8117-6. Archived from the original on 7 October 2022. Retrieved 1 December 2016.
Wakelin SH, Maibach HI, Archer CB (1 June 2002). Systemic Drug Treatment in Dermatology: A Handbook. CRC Press. pp. 32, 35. ISBN 978-1-84076-013-2. Archived from the original on 7 October 2022. Retrieved 1 December 2016.
Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 960ff. ISBN 978-3-88763-075-1.
Goldsmith D, Covic A, Spaak J (12 November 2014). Cardio-Renal Clinical Challenges. Springer. pp. 167–. ISBN 978-3-319-09162-4. Archived from the original on 7 October 2022. Retrieved 17 August 2018.
Seldin DW, Giebisch GH (23 September 1997). Diuretic Agents: Clinical Physiology and Pharmacology. Academic Press. pp. 630–632. ISBN 978-0-08-053046-8. Archived from the original on 4 July 2014.
Aronson JK (2 March 2009). Meyler's Side Effects of Cardiovascular Drugs. Elsevier. pp. 253–258. ISBN 978-0-08-093289-7. Archived from the original on 7 October 2022. Retrieved 16 October 2016.
Carrell DT, Peterson CM (23 March 2010). Reproductive Endocrinology and Infertility: Integrating Modern Clinical and Laboratory Practice. Springer Science & Business Media. pp. 162–. ISBN 978-1-4419-1436-1. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Pescovitz OH, Eugster EA (2004). Pediatric Endocrinology: Mechanisms, Manifestations, and Management. Lippincott Williams & Wilkins. pp. 368–. ISBN 978-0-7817-4059-3.
Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 708, 777, 1087, 1196. ISBN 978-0-7817-1750-2. Archived from the original on 6 October 2022. Retrieved 6 May 2018.
Tsioufis C, Schmieder R, Mancia G (15 August 2016). Interventional Therapies for Secondary and Essential Hypertension. Springer. p. 44. ISBN 978-3-319-34141-5. Archived from the original on 7 October 2022. Retrieved 16 October 2016.
Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Elsevier Science. 1 December 2014. p. 293. ISBN 978-0-444-63391-0.
McInnes GT (2008). Clinical Pharmacology and Therapeutics of Hypertension. Elsevier. p. 125. ISBN 978-0-444-51757-9. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Wilcox CS (22 August 2008). Therapy in Nephrology and Hypertension E-Book: A Companion to Brenner & Rector's The Kidney. Elsevier Health Sciences. pp. 607–. ISBN 978-1-4377-1124-0. Archived from the original on 7 October 2022. Retrieved 17 August 2018.
Jemec G, Revuz J, Leyden JJ (24 November 2006). Hidradenitis Suppurativa. Springer Science & Business Media. pp. 125–. ISBN 978-3-540-33101-8. Archived from the original on 7 October 2022. Retrieved 15 August 2018.
Basson R, Prior JC (1998). "Hormonal Therapy of Gender Dysphoria: The Male-to-Female Transsexual". In Denny D (ed.). Current Concepts in Transgender Identity. Taylor & Francis. pp. 277–296. doi:10.4324/9780203775134. ISBN 978-1-134-82110-5. Archived from the original on 7 October 2022. Retrieved 2 January 2019.
Ainsworth SB (10 November 2014). Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. pp. 486–. ISBN 978-1-118-81959-3. Archived from the original on 8 September 2017.
Little B (29 September 2006). Drugs and Pregnancy: A Handbook. CRC Press. pp. 63–. ISBN 978-0-340-80917-4. Archived from the original on 8 September 2017.
Rubin PC, Ramsey M (30 April 2008). Prescribing in Pregnancy. John Wiley & Sons. pp. 83–. ISBN 978-0-470-69555-5. Archived from the original on 8 September 2017.
Briggs GG, Freeman RK, Yaffe SJ (2011). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. pp. 1349–. ISBN 978-1-60831-708-0. Archived from the original on 8 September 2017.
Gleicher N, Elkayam U, Gleicher N (23 June 1998). Cardiac Problems in Pregnancy: Diagnosis and Management of Maternal and Fetal Heart Disease. John Wiley & Sons. pp. 353–. ISBN 978-0-471-16358-9. Archived from the original on 8 September 2017.
Schaefer C (2001). Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment. Gulf Professional Publishing. pp. 115, 143. ISBN 978-0-444-50763-1. Archived from the original on 8 September 2017.
Upfal J (2006). Australian Drug Guide. Black Inc. pp. 671–. ISBN 978-1-86395-174-6. Archived from the original on 8 September 2017.
Davis MP (28 May 2009). Opioids in Cancer Pain. OUP Oxford. pp. 222–. ISBN 978-0-19-923664-0. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Wolverton SE (8 March 2007). Comprehensive Dermatologic Drug Therapy. Elsevier Health Sciences. pp. 2677–. ISBN 978-1-4377-2070-9. Archived from the original on 7 October 2022. Retrieved 7 May 2017.
International Agency for Research on Cancer, World Health Organization (2001). Some Thyrotropic Agents. World Health Organization. pp. 325–. ISBN 978-92-832-1279-9. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Ginés P, Arroyo V, Rodés J, Schrier RW (15 April 2008). Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. John Wiley & Sons. pp. 229, 231. ISBN 978-1-4051-4370-7. Archived from the original on 7 October 2022. Retrieved 6 May 2018.
Feldman AM (15 April 2008). Heart Failure: Pharmacologic Management. John Wiley & Sons. pp. 89–103. ISBN 978-1-4051-7253-0. Archived from the original on 7 October 2022. Retrieved 13 August 2018.
Walar K (15 June 2015). Pharmacology (6th ed.). Wolter Kluwer Health. pp. 248–249. GGKEY:N57K51AQ0UA.^{[permanent dead link]}
Strauss III JF, Barbieri RL (13 September 2013). Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. pp. 237–. ISBN 978-1-4557-2758-2. Archived from the original on 7 October 2022. Retrieved 13 August 2018.
Haff GG, Triplett NT (23 September 2015). Essentials of Strength Training and Conditioning 4th Edition. Human Kinetics. pp. 76–. ISBN 978-1-4925-0162-6. Archived from the original on 7 October 2022. Retrieved 14 August 2018.
Wu JJ (18 October 2012). Comprehensive Dermatologic Drug Therapy E-Book. Elsevier Health Sciences. pp. 364–. ISBN 978-1-4557-3801-4. Archived from the original on 7 October 2022. Retrieved 6 May 2018.
Coelingh Benni HJ, Vemer HM (15 December 1990). Chronic Hyperandrogenic Anovulation. CRC Press. pp. 152–. ISBN 978-1-85070-322-8. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Watts S, Faingold C, Dunaway G, Crespo L (1 April 2009). Brody's Human Pharmacology - E-Book. Elsevier Health Sciences. pp. 472–. ISBN 978-0-323-07575-6.
Adams KF (28 October 2014). Pharmacologic Approaches to Heart Failure, An Issue of Heart Failure Clinics, E-Book. Elsevier Health Sciences. pp. 562–. ISBN 978-0-323-32612-4. Archived from the original on 7 October 2022. Retrieved 13 August 2018.
Falcone T, Hurd WW (1 January 2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. pp. 271–. ISBN 978-0-323-03309-1. Archived from the original on 7 October 2022. Retrieved 13 August 2018.
Kuntz E, Kuntz HD (11 March 2009). Hepatology: Textbook and Atlas. Springer Science & Business Media. pp. 312–. ISBN 978-3-540-76839-5. Archived from the original on 7 October 2022. Retrieved 13 August 2018.
Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (12 May 2011). Williams Textbook of Endocrinology E-Book. Elsevier Health Sciences. pp. 571–. ISBN 978-1-4377-3600-7.
Aldosterone. Elsevier Science. 23 January 2019. pp. 11, 46. ISBN 978-0-12-817783-9. Archived from the original on 7 October 2022. Retrieved 20 September 2019.
Bland KI, Copeland III EM (9 September 2009). The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Health Sciences. pp. 161–. ISBN 978-1-4377-1121-9. Archived from the original on 7 October 2022. Retrieved 14 September 2017.
Oxford Textbook of Medicine: Vol. 1. Oxford University Press. 2003. pp. 1–. ISBN 978-0-19-262922-7. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Anzenbacher P, Zanger UM (23 February 2012). Metabolism of Drugs and Other Xenobiotics. John Wiley & Sons. pp. 166, 169. ISBN 978-3-527-64632-6. Archived from the original on 7 October 2022. Retrieved 12 August 2018.
Smith BT, Seaward BL, Smith BT (1 November 2014). Pharmacology for Nurses. Jones & Bartlett Publishers. pp. 169–. ISBN 978-1-4496-8940-7. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Ortiz de Montellano PR (13 March 2015). Cytochrome P450: Structure, Mechanism, and Biochemistry. Springer. pp. 867–. ISBN 978-3-319-12108-6. Archived from the original on 7 October 2022. Retrieved 12 August 2018.
Advances in Clinical Chemistry. Academic Press. 31 December 2012. pp. 69–. ISBN 978-0-12-405852-1.
Brittain HG (26 November 2002). Analytical Profiles of Drug Substances and Excipients. Academic Press. p. 309. ISBN 978-0-12-260829-2. Archived from the original on 21 June 2013. Retrieved 27 May 2012.
Jameson JL, De Groot LJ (18 May 2010). Endocrinology - E-Book: Adult and Pediatric. Elsevier Health Sciences. pp. 2401–. ISBN 978-1-4557-1126-0.
Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 1111. ISBN 978-1-4757-2085-3. Archived from the original on 15 February 2017.
The British Encyclopaedia of Medical Practice: Medical progress. Butterworth & Company. 1961. p. 302. Archived from the original on 7 October 2022. Retrieved 2 February 2018.
Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1279–1280. ISBN 978-3-13-179275-4. Archived from the original on 7 October 2022. Retrieved 27 December 2016.
Landau R, Achilladelis B, Scriabine A (1999). Pharmaceutical Innovation: Revolutionizing Human Health. Chemical Heritage Foundation. pp. 198–. ISBN 978-0-941901-21-5. Archived from the original on 7 October 2022. Retrieved 27 December 2016.
Jugdutt BI (19 February 2014). Aging and Heart Failure: Mechanisms and Management. Springer Science & Business Media. pp. 175–. ISBN 978-1-4939-0268-2. Archived from the original on 7 October 2022. Retrieved 27 December 2016.
Wermuth CG (2 May 2011). The Practice of Medicinal Chemistry. Academic Press. pp. 34–. ISBN 978-0-08-056877-5. Archived from the original on 21 June 2013.
Curtis M (2014). Glass' Office Gynecology. Lippincott Williams & Wilkins. pp. 47–. ISBN 978-1-60831-820-9.
Shah D, Bhathena RK, Shroff S (2004). The Polycystic Ovary Syndrome. Orient Blackswan. pp. 78–. ISBN 978-81-250-2633-4. Archived from the original on 7 October 2022. Retrieved 4 July 2017.
Hillard PJ (29 March 2013). Practical Pediatric and Adolescent Gynecology. John Wiley & Sons. pp. 371–. ISBN 978-1-118-53857-9. Archived from the original on 7 October 2022. Retrieved 4 July 2017.
Dorfman RI (5 December 2016). Steroidal Activity in Experimental Animals and Man. Elsevier Science. pp. 392–. ISBN 978-1-4832-7299-3.
Gláz E, Vecsei P (11 January 2017). Aldosterone: International Series of Monographs in Pure and Applied Biology. Elsevier Science. p. 379. ISBN 978-1-4831-5997-3. Archived from the original on 10 October 2022. Retrieved 31 December 2020.
Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261ff. ISBN 978-0-7514-0499-9. Archived from the original on 7 October 2022. Retrieved 1 December 2016.
Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 266–. ISBN 978-1-4612-5476-8. Archived from the original on 7 October 2022. Retrieved 30 July 2017.

chemspider.com

"Spironolactone | C24H32O4S". ChemSpider. Royal Society of Chemistry. Archived from the original on 9 September 2017. Retrieved 4 July 2017.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Spironolactone Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Sica DA (January 2005). "Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis". Heart Failure Reviews. 10 (1): 23–9. doi:10.1007/s10741-005-2345-1. PMID 15947888. S2CID 21437788.
Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A (February 2017). "Spironolactone". Journal of Pain and Symptom Management. 53 (2): 288–292. doi:10.1016/j.jpainsymman.2016.12.320. PMID 28024992.
Takamura N, Maruyama T, Ahmed S, Suenaga A, Otagiri M (April 1997). "Interactions of aldosterone antagonist diuretics with human serum proteins". Pharmaceutical Research. 14 (4): 522–6. doi:10.1023/A:1012168020545. PMID 9144743. S2CID 13227538.
Los LE, Pitzenberger SM, Ramjit HG, Coddington AB, Colby HD (1994). "Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites". Drug Metabolism and Disposition. 22 (6): 903–8. doi:10.1016/S0090-9556(25)08434-X. PMID 7895608.
Draganov DI, La Du BN (January 2004). "Pharmacogenetics of paraoxonases: a brief review". Naunyn-Schmiedeberg's Archives of Pharmacology. 369 (1): 78–88. doi:10.1007/s00210-003-0833-1. hdl:2027.42/46312. PMID 14579013. S2CID 15825605.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. (September 1999). "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators". The New England Journal of Medicine. 341 (10): 709–717. doi:10.1056/NEJM199909023411001. PMID 10471456.
Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, et al. (August 2018). "Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials". Medicine. 97 (35): e11942. doi:10.1097/MD.0000000000011942. PMC 6392615. PMID 30170387.
Sinnott SJ, Tomlinson LA, Root AA, Mathur R, Mansfield KE, Smeeth L, et al. (February 2017). "Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis" (PDF). European Journal of Preventive Cardiology. 24 (3): 228–238. doi:10.1177/2047487316675194. PMID 27856806.
Liszewski W, Boull C (April 2019). "Lack of evidence for feminization of males exposed to spironolactone in utero: A systematic review". Journal of the American Academy of Dermatology. 80 (4): 1147–1148. doi:10.1016/j.jaad.2018.10.023. PMID 30352280. S2CID 53022388.
Landau E, Amar L (June 2016). "Primary aldosteronism and pregnancy". Ann Endocrinol (Paris). 77 (2): 148–60. doi:10.1016/j.ando.2016.04.009. PMID 27156905.
Deng N, Zhong J, Deng Z, Chen M, Yan L, Li H, et al. (25 July 2024). "Case report: A pregnant woman accidental treated with spironolactone in mid-gestation". Frontiers in Pharmacology. 15: 1404251. doi:10.3389/fphar.2024.1404251. PMC 11306061. PMID 39119600.
Burinkul S, Panyakhamlerd K, Suwan A, Tuntiviriyapun P, Wainipitapong S (July 2021). "Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial". The Journal of Sexual Medicine. 18 (7): 1299–1307. doi:10.1016/j.jsxm.2021.05.003. PMID 34274044.
Sehgal I (2023). "Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations". Frontiers in Endocrinology. 14: 1184024. doi:10.3389/fendo.2023.1184024. PMC 10355117. PMID 37476490.
Prior JC, Vigna YM, Watson D (1989). "Spironolactone with Physiological Female Steroids for Presurgical Therapy of Male-To-Female Transsexualism". Archives of Sexual Behavior. 18 (1): 49–57. doi:10.1007/BF01579291. PMID 2540730.
Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, et al. (November 2012). "Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice". European Heart Journal. 33 (22): 2782–2795. doi:10.1093/eurheartj/ehs257. PMID 22942339.
Berbenetz NM, Mrkobrada M (December 2016). "Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis". BMC Cardiovascular Disorders. 16 (1): 246. doi:10.1186/s12872-016-0425-x. PMC 5134129. PMID 27905877.
Bayoumi E, Lam PH, Dooley DJ, Singh S, Faselis C, Morgan CJ, et al. (January 2019). "Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction". The American Journal of Medicine. 132 (1): 71–80.e1. doi:10.1016/j.amjmed.2018.09.011. PMC 6511886. PMID 30240686.
Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, et al. (August 2018). "Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials". Medicine. 97 (35): e11942. doi:10.1097/md.0000000000011942. PMC 6392615. PMID 30170387.
Tsujimoto T, Kajio H (December 2020). "Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension". Journal of the American Heart Association. 9 (23): e018827. doi:10.1161/JAHA.120.018827. PMC 7763779. PMID 33222584.
Delyani JA (April 2000). "Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology". Kidney International. 57 (4): 1408–1411. doi:10.1046/j.1523-1755.2000.00983.x. PMID 10760075.
Endou H, Hosoyamada M (1995). "Potassium-Retaining Diuretics: Aldosterone Antagonists". Diuretics. Handbook of Experimental Pharmacology. Vol. 117. Springer. pp. 335–361. doi:10.1007/978-3-642-79565-7_9. ISBN 978-3-642-79567-1. ISSN 0171-2004.
Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, et al. (May 2023). "Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial". BMJ. 381: e074349. doi:10.1136/bmj-2022-074349. PMC 10543374. PMID 37192767.
Kow CS, Ramachandram DS, Hasan SS, Thiruchelvam K (May 2025). "Spironolactone for the Treatment of Moderate to Severe Acne in Adult Women: A Systematic Review and Meta-Analysis of Randomised Controlled Trials". The Australasian Journal of Dermatology. 66 (3): 165–168. doi:10.1111/ajd.14428. PMID 39912292.
Hughes BR, Cunliffe WJ (May 1988). "Tolerance of spironolactone". The British Journal of Dermatology. 118 (5): 687–691. doi:10.1111/j.1365-2133.1988.tb02571.x. PMID 2969259. S2CID 208286107.
Loy R, Seibel MM (December 1988). "Evaluation and therapy of polycystic ovarian syndrome". Endocrinology and Metabolism Clinics of North America. 17 (4): 785–813. doi:10.1016/S0889-8529(18)30410-9. PMID 3143568.
Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. (June 2017). "Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure". Journal of the American College of Cardiology. 69 (25): 3042–3051. doi:10.1016/j.jacc.2017.04.042. PMID 28641794.
Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, et al. (January 2017). "Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis". Circulation. Heart Failure. 10 (1): e003529. doi:10.1161/CIRCHEARTFAILURE.116.003529. PMC 5265698. PMID 28087688.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. (October 2013). "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Journal of the American College of Cardiology. 62 (16): e147 – e239. doi:10.1016/j.jacc.2013.05.019. PMID 23747642.
Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, et al. (August 2018). "Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials". Medicine. 97 (35): e11942. doi:10.1097/MD.0000000000011942. PMC 6392615. PMID 30170387.
Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E (December 2018). "Role of spironolactone in the treatment of heart failure with preserved ejection fraction". Annals of Translational Medicine. 6 (23): 461. doi:10.21037/atm.2018.11.16. PMC 6312809. PMID 30603649.
Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N, et al. (August 2012). "Eplerenone is not superior to older and less expensive aldosterone antagonists". The American Journal of Medicine. 125 (8): 817–25. doi:10.1016/j.amjmed.2011.12.018. PMID 22840667.
Elshahat A, Mansour A, Ellabban M, Diaa A, Hassan A, Fawzy A, et al. (September 2024). "Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis". BMC Cardiovascular Disorders. 24 (1): 489. doi:10.1186/s12872-024-04103-7. PMC 11395778. PMID 39271992.
Frankenstein L, Seide S, Täger T, Jensen K, Fröhlich H, Clark AL, et al. (March 2020). "Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials". Heart Failure Reviews. 25 (2): 161–171. doi:10.1007/s10741-019-09832-y. PMID 31364027.
Batterink J, Stabler SN, Tejani AM, Fowkes CT (August 2010). "Spironolactone for hypertension". The Cochrane Database of Systematic Reviews (8): CD008169. doi:10.1002/14651858.CD008169.pub2. PMID 20687095.
Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, Lales G, Mitas C, Doumas M (2018). "Mineralocorticoid Receptor Antagonists in Primary Aldosteronism". Curr Pharm Des. 24 (46): 5508–5516. doi:10.2174/1381612825666190311130138. PMID 30854950. S2CID 73727928.
Forestiero V, Sconfienza E, Mulatero P, Monticone S (May 2022). "Primary aldosteronism in pregnancy". Rev Endocr Metab Disord. 24 (1): 39–48. doi:10.1007/s11154-022-09729-6. PMC 9884655. PMID 35536535. S2CID 248574316.
Riester A, Reincke M (January 2015). "Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy". Eur J Endocrinol. 172 (1): R23–30. doi:10.1530/EJE-14-0444. PMID 25163723. S2CID 43338556.
Araujo-Castro M (October 2020). "Treatment of primary hyperaldosteronism". Med Clin (Barc). 155 (7): 302–308. doi:10.1016/j.medcli.2020.04.029. PMID 32586668. S2CID 225657804.
Zouboulis CC, Degitz K (2004). "Androgen action on human skin -- from basic research to clinical significance". Experimental Dermatology. 13 (Suppl 4): 5–10. doi:10.1111/j.1600-0625.2004.00255.x. PMID 15507105. S2CID 34863608.
Diamanti-Kandarakis E, Tolis G, Duleba AJ (1995). "Androgens and therapeutic aspects of antiandrogens in women". Journal of the Society for Gynecologic Investigation. 2 (4): 577–92. doi:10.1177/107155769500200401. PMID 9420861. S2CID 32242838.
Katsambas AD, Dessinioti C (2010). "Hormonal therapy for acne: why not as first line therapy? facts and controversies". Clinics in Dermatology. 28 (1): 17–23. doi:10.1016/j.clindermatol.2009.03.006. PMID 20082945.
Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ (April 2017). "Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review". American Journal of Clinical Dermatology. 18 (2): 169–191. doi:10.1007/s40257-016-0245-x. PMC 5360829. PMID 28155090.
Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, et al. (May 2023). "Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial". BMJ. 381: e074349. doi:10.1136/bmj-2022-074349. PMC 10543374. PMID 37192767. S2CID 258717921.
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. (May 2016). "Guidelines of care for the management of acne vulgaris". Journal of the American Academy of Dermatology. 74 (5): 945–73.e33. doi:10.1016/j.jaad.2015.12.037. PMID 26897386.
Shaw JC (October 1996). "Antiandrogen and hormonal treatment of acne". Dermatologic Clinics. 14 (4): 803–11. doi:10.1016/S0733-8635(05)70405-8. PMID 9238337.
Somani N, Turvy D (July 2014). "Hirsutism: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 247–66. doi:10.1007/s40257-014-0078-4. PMID 24889738. S2CID 45234892.
Harfmann KL, Bechtel MA (March 2015). "Hair loss in women". Clinical Obstetrics and Gynecology. 58 (1): 185–99. doi:10.1097/GRF.0000000000000081. PMID 25517757. S2CID 20364810.
Cousen P, Messenger A (May 2010). "Female pattern hair loss in complete androgen insensitivity syndrome". The British Journal of Dermatology. 162 (5): 1135–7. doi:10.1111/j.1365-2133.2010.09661.x. PMID 20128792. S2CID 205259907.
Iswaran TJ, Imai M, Betton GR, Siddall RA (May 1997). "An overview of animal toxicology studies with bicalutamide (ICI 176,334)". The Journal of Toxicological Sciences. 22 (2): 75–88. doi:10.2131/jts.22.2_75. PMID 9198005.
Schmidt JB (1998). "Other antiandrogens". Dermatology. 196 (1): 153–7. doi:10.1159/000017850. PMID 9557251. S2CID 22119267.
Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, et al. (September 2009). "Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline". The Journal of Clinical Endocrinology and Metabolism. 94 (9): 3132–54. doi:10.1210/jc.2009-0345. PMID 19509099.
Prior JC, Vigna YM, Watson D (February 1989). "Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism". Archives of Sexual Behavior. 18 (1): 49–57. doi:10.1007/bf01579291. PMID 2540730. S2CID 22802329.
Cunliffe WJ, Bottomley WW (September 1992). "Antiandrogens and acne. A topical approach?". Archives of Dermatology. 128 (9): 1261–4. doi:10.1001/archderm.1992.01680190117017. PMID 1387779.
Vincenzi C, Trevisi P, Farina P, Stinchi C, Tosti A (November 1993). "Facial contact dermatitis due to spironolactone in an anti-acne cream". Contact Dermatitis. 29 (5): 277–8. doi:10.1111/j.1600-0536.1993.tb03569.x. PMID 8112074. S2CID 19134415.
Benvenga S (2009). "Therapy of Hirsutism". Diagnosis and Management of Polycystic Ovary Syndrome. Springer. pp. 233–242. doi:10.1007/978-0-387-09718-3_19. ISBN 978-0-387-09717-6.
van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N (April 2015). "Interventions for hirsutism (excluding laser and photoepilation therapy alone)". The Cochrane Database of Systematic Reviews. 2015 (4): CD010334. doi:10.1002/14651858.CD010334.pub2. PMC 6481758. PMID 25918921.
Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, et al. (April 2018). "Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis". The Journal of Clinical Endocrinology and Metabolism. 103 (4): 1258–1264. doi:10.1210/jc.2017-02052. PMID 29522176. S2CID 3783739.
Erem C (2013). "Update on idiopathic hirsutism: diagnosis and treatment". Acta Clinica Belgica. 68 (4): 268–74. doi:10.2143/ACB.3267. PMID 24455796. S2CID 39120534.
Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, et al. (March 2018). "Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial". The Journal of Clinical Endocrinology and Metabolism. 103 (3): 824–838. doi:10.1210/jc.2017-01186. PMID 29211888. S2CID 3784055.
Kamangar F, Shinkai K (October 2012). "Acne in the adult female patient: a practical approach". International Journal of Dermatology. 51 (10): 1162–74. doi:10.1111/j.1365-4632.2012.05519.x. PMID 22994662. S2CID 5777817.
Diamanti-Kandarakis E (September 1999). "Current aspects of antiandrogen therapy in women". Current Pharmaceutical Design. 5 (9): 707–23. doi:10.2174/1381612805666230111201150. PMID 10495361.
Trivedi MK, Shinkai K, Murase JE (March 2017). "A Review of hormone-based therapies to treat adult acne vulgaris in women". International Journal of Women's Dermatology. 3 (1): 44–52. doi:10.1016/j.ijwd.2017.02.018. PMC 5419026. PMID 28492054.
Yasa C, Dural Ö, Bastu E, Uğurlucan FG (2016). "Hirsutism, Acne, and Hair Loss: Management of Hyperandrogenic Cutaneous Manifestations of Polycystic Ovary Syndrome". Gynecology Obstetrics & Reproductive Medicine. 23 (2): 110–119. doi:10.21613/GORM.2016.613. ISSN 1300-4751.
Barros B, Thiboutot D (2017). "Hormonal therapies for acne". Clinics in Dermatology. 35 (2): 168–172. doi:10.1016/j.clindermatol.2016.10.009. PMID 28274354.
Hassoun LA, Chahal DS, Sivamani RK, Larsen LN (June 2016). "The use of hormonal agents in the treatment of acne". Seminars in Cutaneous Medicine and Surgery. 35 (2): 68–73. doi:10.12788/j.sder.2016.027 (inactive 1 November 2024). PMID 27416311.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR (June 2019). "Androgens in women: Hormone-modulating therapies for skin disease". Journal of the American Academy of Dermatology. 80 (6): 1509–1521. doi:10.1016/j.jaad.2018.08.061. PMID 30312645. S2CID 52973096.
van Zuuren EJ, Fedorowicz Z, Schoones J (May 2016). "Interventions for female pattern hair loss". The Cochrane Database of Systematic Reviews. 2016 (5): CD007628. doi:10.1002/14651858.CD007628.pub4. PMC 6457957. PMID 27225981.
Brown J, Farquhar C, Lee O, Toomath R, Jepson RG (April 2009). "Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne". The Cochrane Database of Systematic Reviews (2): CD000194. doi:10.1002/14651858.CD000194.pub2. hdl:2292/9640. PMID 19370553.
Hammerstein J (1990). "Antiandrogens: Clinical Aspects". Hair and Hair Diseases. Springer. pp. 827–886. doi:10.1007/978-3-642-74612-3_35. ISBN 978-3-642-74614-7.
Sundar S, Dickinson PD (February 2012). "Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate". BMJ Case Reports. 2012: bcr1120115238. doi:10.1136/bcr.11.2011.5238. PMC 3291010. PMID 22665559.
Randolph JF (December 2018). "Gender-Affirming Hormone Therapy for Transgender Females". Clinical Obstetrics and Gynecology. 61 (4): 705–721. doi:10.1097/GRF.0000000000000396. PMID 30256230.
Kolkhof P, Bärfacker L (July 2017). "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". The Journal of Endocrinology. 234 (1): T125 – T140. doi:10.1530/JOE-16-0600. PMC 5488394. PMID 28634268.
Loriaux DL (November 1976). "Spironolactone and endocrine dysfunction". Annals of Internal Medicine. 85 (5): 630–6. doi:10.7326/0003-4819-85-5-630. PMID 984618.
Secora AM, Shin JI, Qiao Y, Alexander GC, Chang AR, Inker LA, et al. (November 2020). "Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure". Mayo Clinic Proceedings. 95 (11): 2408–2419. doi:10.1016/j.mayocp.2020.03.035. PMC 8005315. PMID 33153631.
Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M (August 2006). "Spironolactone and risk of upper gastrointestinal events: population based case-control study". BMJ. 333 (7563): 330. doi:10.1136/bmj.38883.479549.2F. PMC 1539051. PMID 16840442.
Gulmez SE, Lassen AT, Aalykke C, Dall M, Andries A, Andersen BS, et al. (August 2008). "Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study". Br J Clin Pharmacol. 66 (2): 294–9. doi:10.1111/j.1365-2125.2008.03205.x. PMC 2492928. PMID 18507655.
Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. (December 2015). "Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone". International Journal of Cardiology. 200: 25–9. doi:10.1016/j.ijcard.2015.05.127. PMID 26404748.
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. (August 2004). "Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study". The New England Journal of Medicine. 351 (6): 543–51. doi:10.1056/NEJMoa040135. PMID 15295047.
Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, et al. (November 2012). "Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice". European Heart Journal. 33 (22): 2782–95. doi:10.1093/eurheartj/ehs257. PMID 22942339.
Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM (May 2010). "Spironolactone use and renal toxicity: population based longitudinal analysis". BMJ. 340: c1768. doi:10.1136/bmj.c1768. PMID 20483947. S2CID 14815504.
Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, Garg AX, et al. (September 2011). "Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study". BMJ. 343: d5228. doi:10.1136/bmj.d5228. PMC 3171211. PMID 21911446.
Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN (March 2015). "Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone". CMAJ. 187 (4): E138 – E143. doi:10.1503/cmaj.140816. PMC 4347789. PMID 25646289.
Plovanich M, Weng QY, Mostaghimi A (September 2015). "Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne". JAMA Dermatology. 151 (9): 941–4. doi:10.1001/jamadermatol.2015.34. PMID 25796182.
Millington K, Liu E, Chan YM (May 2019). "The Utility of Potassium Monitoring in Gender-Diverse Adolescents Taking Spironolactone". Journal of the Endocrine Society. 3 (5): 1031–1038. doi:10.1210/js.2019-00030. PMC 6497918. PMID 31065620.
Hayes H, Russell R, Haugen A, Nagavally S, Sarvaideo J (October 2022). "The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone". Journal of the Endocrine Society. 6 (11): bvac133. doi:10.1210/jendso/bvac133. PMC 9562816. PMID 36267595.
Conn JJ, Jacobs HS (July 1998). "Managing hirsutism in gynaecological practice". British Journal of Obstetrics and Gynaecology. 105 (7): 687–96. doi:10.1111/j.1471-0528.1998.tb10197.x. PMID 9692407. S2CID 34751086.
Ménard J (March 2004). "The 45-year story of the development of an anti-aldosterone more specific than spironolactone". Molecular and Cellular Endocrinology. 217 (1–2): 45–52. doi:10.1016/j.mce.2003.10.008. PMID 15134800. S2CID 19701784.
Thompson DF, Carter JR (1993). "Drug-induced gynecomastia". Pharmacotherapy. 13 (1): 37–45. doi:10.1002/j.1875-9114.1993.tb02688.x. PMID 8094898. S2CID 30322620.
Eckman A, Dobs A (November 2008). "Drug-induced gynecomastia". Expert Opinion on Drug Safety. 7 (6): 691–702. doi:10.1517/14740330802442382. PMID 18983216. S2CID 72716346.
Mathur R, Braunstein GD (1997). "Gynecomastia: pathomechanisms and treatment strategies". Hormone Research. 48 (3): 95–102. doi:10.1159/000185497. PMID 11546925.
Christy NA, Franks AS, Cross LB (September 2005). "Spironolactone for hirsutism in polycystic ovary syndrome". The Annals of Pharmacotherapy. 39 (9): 1517–21. doi:10.1345/aph.1G025. PMID 16076921. S2CID 45708497.
Spritzer PM, Lisboa KO, Mattiello S, Lhullier F (May 2000). "Spironolactone as a single agent for long-term therapy of hirsute patients". Clinical Endocrinology. 52 (5): 587–94. doi:10.1046/j.1365-2265.2000.00982.x. PMID 10792338. S2CID 40606594.
Rabe T, Grunwald K, Feldmann K, Runnebaum B (2009). "Treatment of hyperandrogenism in women". Gynecological Endocrinology. 10 (sup3): 1–44. doi:10.3109/09513599609045658. ISSN 0951-3590.
McMullen GR, Van Herle AJ (December 1993). "Hirsutism and the effectiveness of spironolactone in its management". Journal of Endocrinological Investigation. 16 (11): 925–32. doi:10.1007/BF03348960. PMID 8144871. S2CID 42231952.
Nakajima ST, Brumsted JR, Riddick DH, Gibson M (July 1989). "Absence of progestational activity of oral spironolactone". Fertility and Sterility. 52 (1): 155–8. doi:10.1016/s0015-0282(16)60807-5. PMID 2744183.
Olsson HL, Olsson ML (2020). "The Menstrual Cycle and Risk of Breast Cancer: A Review". Frontiers in Oncology. 10: 21. doi:10.3389/fonc.2020.00021. PMC 6993118. PMID 32038990.
ter Heegde F, De Rijk RH, Vinkers CH (February 2015). "The brain mineralocorticoid receptor and stress resilience". Psychoneuroendocrinology. 52: 92–110. doi:10.1016/j.psyneuen.2014.10.022. hdl:1874/331554. PMID 25459896. S2CID 14297156.
Schultebraucks K (2016). The Role of the Mineralocorticoid Receptor for Cognitive Function, Mood and Social Cognition (PDF) (Dissertation). doi:10.17169/refubium-6940. Archived from the original on 28 December 2018. Retrieved 27 December 2018.
Holsboer F (1999). "The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety". Journal of Psychiatric Research. 33 (3): 181–214. doi:10.1016/S0022-3956(98)90056-5. PMID 10367986.
Basson R, Prior JC (1998). "Hormonal Therapy of Gender Dysphoria: The Male-to-Female Transsexual". In Denny D (ed.). Current Concepts in Transgender Identity. Taylor & Francis. pp. 277–296. doi:10.4324/9780203775134. ISBN 978-1-134-82110-5. Archived from the original on 7 October 2022. Retrieved 2 January 2019.
Baldani DP, Skrgatic L, Ougouag R, Kasum M (February 2018). "The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment". Gynecol Endocrinol. 34 (2): 87–91. doi:10.1080/09513590.2017.1381681. PMID 28944709. S2CID 205631980.
Nakhjavani M, Hamidi S, Esteghamati A, Abbasi M, Nosratian-Jahromi S, Pasalar P (October 2009). "Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism". Br J Clin Pharmacol. 68 (4): 634–7. doi:10.1111/j.1365-2125.2009.03483.x. PMC 2780289. PMID 19843067.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. (June 2019). "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 139 (25): e1082 – e1143. doi:10.1161/CIR.0000000000000625. PMC 7403606. PMID 30586774.
Coleman E, Radix AE, Bouman WP, Brown GR, de Vries AL, Deutsch MB, et al. (August 2022). "Standards of Care for the Health of Transgender and Gender Diverse People, Version 8". International Journal of Transgender Health. 23 (Suppl 1): S1 – S259. doi:10.1080/26895269.2022.2100644. ISSN 2689-5269. PMC 9553112. PMID 36238954.
Godsland IF, Wynn V, Crook D, Miller NE (December 1987). "Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions". American Heart Journal. 114 (6): 1467–1503. doi:10.1016/0002-8703(87)90552-7. PMID 3318361.
Cignarella A, Mioni R, Sabbadin C, Dassie F, Parolin M, Vettor R, et al. (December 2020). "Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS". Int J Mol Sci. 21 (24): 9554. doi:10.3390/ijms21249554. PMC 7765466. PMID 33334002.
Lopes RJ, Lourenço AP, Mascarenhas J, Azevedo A, Bettencourt P (November 2008). "Safety of spironolactone use in ambulatory heart failure patients". Clinical Cardiology. 31 (11): 509–13. doi:10.1002/clc.20284. PMC 6652974. PMID 19006114.
Thai KE, Sinclair RD (August 2001). "Spironolactone-induced hepatitis". The Australasian Journal of Dermatology. 42 (3): 180–2. doi:10.1046/j.1440-0960.2001.00510.x. PMID 11488711. S2CID 12160891.
Garthwaite SM, McMahon EG (March 2004). "The evolution of aldosterone antagonists". Molecular and Cellular Endocrinology. 217 (1–2): 27–31. doi:10.1016/j.mce.2003.10.005. PMID 15134797. S2CID 8499861.
Shaw JC (February 1991). "Spironolactone in dermatologic therapy". Journal of the American Academy of Dermatology. 24 (2 Pt 1): 236–43. doi:10.1016/0190-9622(91)70034-Y. PMID 1826112.
Leinung MC, Feustel PJ, Joseph J (2018). "Hormonal Treatment of Transgender Women with Oral Estradiol". Transgender Health. 3 (1): 74–81. doi:10.1089/trgh.2017.0035. PMC 5944393. PMID 29756046.
Jhajra S, Ramesh Varkhede N, Suresh Ahire D, Vidyasagar Naik B, Prasad B, Paliwal J, et al. (2012). "Extrahepatic Drug-Metabolizing Enzymes and Their Significance". Encyclopedia of Drug Metabolism and Interactions. Wiley. pp. 1–99. doi:10.1002/9780470921920.edm028. ISBN 978-0-470-92192-0.
Armanini D, Andrisani A, Bordin L, Sabbadin C (September 2016). "Spironolactone in the treatment of polycystic ovary syndrome". Expert Opinion on Pharmacotherapy. 17 (13): 1713–5. doi:10.1080/14656566.2016.1215430. PMID 27450358. S2CID 19345088.
Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, et al. (March 2007). "Treatment of polycystic ovary syndrome with spironolactone plus licorice". European Journal of Obstetrics, Gynecology, and Reproductive Biology. 131 (1): 61–67. doi:10.1016/j.ejogrb.2006.10.013. PMID 17113210.
Salassa RM, Mattox VR, Rosevear JW (November 1962). "Inhibition of the "mineralocorticoid" activity of licorice by spironolactone". The Journal of Clinical Endocrinology and Metabolism. 22 (11): 1156–9. doi:10.1210/jcem-22-11-1156. PMID 13991036.
Omar HR, Komarova I, El-Ghonemi M, Fathy A, Rashad R, Abdelmalak HD, et al. (August 2012). "Licorice abuse: time to send a warning message". Therapeutic Advances in Endocrinology and Metabolism. 3 (4): 125–38. doi:10.1177/2042018812454322. PMC 3498851. PMID 23185686.
Lin SH, Yang SS, Chau T, Halperin ML (March 2003). "An unusual cause of hypokalemic paralysis: chronic licorice ingestion". The American Journal of the Medical Sciences. 325 (3): 153–6. doi:10.1097/00000441-200303000-00008. PMID 12640291.
Parthasarathy HK, MacDonald TM (March 2007). "Mineralocorticoid receptor antagonists". Current Hypertension Reports. 9 (1): 45–52. doi:10.1007/s11906-007-0009-3. PMID 17362671. S2CID 2090391.
Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, et al. (April 2010). "Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study". Journal of Psychiatric Research. 44 (6): 339–46. doi:10.1016/j.jpsychires.2009.10.006. PMID 19909979.
Mostalac-Preciado CR, de Gortari P, López-Rubalcava C (September 2011). "Antidepressant-like effects of mineralocorticoid but not glucocorticoid antagonists in the lateral septum: interactions with the serotonergic system". Behavioural Brain Research. 223 (1): 88–98. doi:10.1016/j.bbr.2011.04.008. PMID 21515309. S2CID 26986501.
Agusti G, Bourgeois S, Cartiser N, Fessi H, Le Borgne M, Lomberget T (January 2013). "A safe and practical method for the preparation of 7α-thioether and thioester derivatives of spironolactone". Steroids. 78 (1): 102–7. doi:10.1016/j.steroids.2012.09.005. PMID 23063964. S2CID 8992318.
Tamargo J, Segura J, Ruilope LM (April 2014). "Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents". Expert Opinion on Pharmacotherapy. 15 (5): 605–21. doi:10.1517/14656566.2014.879117. PMID 24456327. S2CID 2338377.
Doggrell SA, Brown L (May 2001). "The spironolactone renaissance". Expert Opinion on Investigational Drugs. 10 (5): 943–54. doi:10.1517/13543784.10.5.943. PMID 11322868. S2CID 39820875.
Tremblay RR (May 1986). "Treatment of hirsutism with spironolactone". Clinics in Endocrinology and Metabolism. 15 (2): 363–71. doi:10.1016/S0300-595X(86)80030-5. PMID 2941190.
Shaw JC (November 1996). "Antiandrogen therapy in dermatology". International Journal of Dermatology. 35 (11): 770–8. doi:10.1111/j.1365-4362.1996.tb02970.x. PMID 8915726. S2CID 39334280.
Colby HD (April 1981). "Chemical suppression of steroidogenesis". Environmental Health Perspectives. 38: 119–27. Bibcode:1981EnvHP..38..119C. doi:10.1289/ehp.8138119. PMC 1568425. PMID 6786868.
Rocca ML, Venturella R, Mocciaro R, Di Cello A, Sacchinelli A, Russo V, et al. (June 2015). "Polycystic ovary syndrome: chemical pharmacotherapy". Expert Opinion on Pharmacotherapy. 16 (9): 1369–93. doi:10.1517/14656566.2015.1047344. PMID 26001184. S2CID 43770017.
Ye P, Yamashita T, Pollock DM, Sasano H, Rainey WE (January 2009). "Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis". Hormone and Metabolic Research. 41 (1): 35–9. doi:10.1055/s-0028-1087188. PMC 4277847. PMID 18819053.
Satoh T, Itoh S, Seki T, Itoh S, Nomura N, Yoshizawa I (October 2002). "On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production". The Journal of Steroid Biochemistry and Molecular Biology. 82 (2–3): 209–16. doi:10.1016/S0960-0760(02)00154-1. PMID 12477487. S2CID 9972497.
Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH (October 1977). "Pathophysiology of spironolactone-induced gynecomastia". Annals of Internal Medicine. 87 (4): 398–403. doi:10.7326/0003-4819-87-4-398. PMID 907238.
Poirier D (March 2003). "Inhibitors of 17 beta-hydroxysteroid dehydrogenases". Current Medicinal Chemistry. 10 (6): 453–77. doi:10.2174/0929867033368222. PMID 12570693.
Poirier D (July 2009). "Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases". Anti-Cancer Agents in Medicinal Chemistry. 9 (6): 642–60. doi:10.2174/187152009788680000. PMID 19601747.
Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M (December 2013). "Spironolactone use and the risk of breast and gynecologic cancers". Cancer Epidemiology. 37 (6): 870–5. doi:10.1016/j.canep.2013.10.004. PMID 24189467.
Soubhye J, Alard IC, van Antwerpen P, Dufrasne F (2015). "Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis". Future Medicinal Chemistry. 7 (11): 1431–56. doi:10.4155/fmc.15.74. PMID 26230882.
Berardelli R, Karamouzis I, D'Angelo V, Zichi C, Fussotto B, Giordano R, et al. (February 2013). "Role of mineralocorticoid receptors on the hypothalamus-pituitary-adrenal axis in humans". Endocrine. 43 (1): 51–8. doi:10.1007/s12020-012-9750-8. PMID 22836869. S2CID 34916537.
Otte C, Moritz S, Yassouridis A, Koop M, Madrischewski AM, Wiedemann K, et al. (January 2007). "Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition". Neuropsychopharmacology. 32 (1): 232–8. doi:10.1038/sj.npp.1301217. PMID 17035932. S2CID 10624783.
Hinkelmann K, Hellmann-Regen J, Wingenfeld K, Kuehl LK, Mews M, Fleischer J, et al. (November 2016). "Mineralocorticoid receptor function in depressed patients and healthy individuals". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 71: 183–8. doi:10.1016/j.pnpbp.2016.08.003. PMID 27519144. S2CID 4775178.
Abshagen U, Spörl S, L'age M (February 1978). "Non-interaction of spironolactone medication and cortisol metabolism in man". Klinische Wochenschrift. 56 (3): 135–8. doi:10.1007/BF01478568. PMID 628197. S2CID 30885047.
Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, et al. (November 2010). "Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure". American Heart Journal. 160 (5): 915–21. doi:10.1016/j.ahj.2010.04.024. PMID 21095280.
Kliewer SA, Goodwin B, Willson TM (October 2002). "The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism". Endocrine Reviews. 23 (5): 687–702. doi:10.1210/er.2001-0038. PMID 12372848.
Sabbadin C, Andrisani A, Zermiani M, Donà G, Bordin L, Ragazzi E, et al. (September 2016). "Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI". Journal of Endocrinological Investigation. 39 (9): 1015–21. doi:10.1007/s40618-016-0466-0. PMID 27072668. S2CID 34201900.
Delyani JA (April 2000). "Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology". Kidney International. 57 (4): 1408–11. doi:10.1046/j.1523-1755.2000.00983.x. PMID 10760075.
Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (September 1998). "The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions". The Journal of Clinical Investigation. 102 (5): 1016–23. doi:10.1172/JCI3703. PMC 508967. PMID 9727070.
Karim A (1978). "Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability". Drug Metabolism Reviews. 8 (1): 151–88. doi:10.3109/03602537808993782. PMID 363379.
Beermann B (1984). "Aspects on pharmacokinetics of some diuretics". Acta Pharmacologica et Toxicologica. 54 (Suppl 1): 17–29. doi:10.1111/j.1600-0773.1984.tb03626.x. PMID 6369882.
Overdiek HW, Merkus FW (1987). "The metabolism and biopharmaceutics of spironolactone in man". Reviews on Drug Metabolism and Drug Interactions. 5 (4): 273–302. doi:10.1515/DMDI.1987.5.4.273. PMID 3333882. S2CID 29482256.
Brater DC (November 2011). "Update in diuretic therapy: clinical pharmacology". Seminars in Nephrology. 31 (6): 483–94. doi:10.1016/j.semnephrol.2011.09.003. PMID 22099505.
Kolkhof P, Borden SA (March 2012). "Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics". Molecular and Cellular Endocrinology. 350 (2): 310–7. doi:10.1016/j.mce.2011.06.025. PMID 21771637. S2CID 36894459.
Yang J, Young MJ (April 2016). "Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences". Current Opinion in Pharmacology. 27: 78–85. doi:10.1016/j.coph.2016.02.005. PMID 26939027.
Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B (2017). "Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside". Heart Failure. Handbook of Experimental Pharmacology. Vol. 243. Springer. pp. 271–305. doi:10.1007/164_2016_76. ISBN 978-3-319-59658-7. PMID 27830348.
Jankowski A, Skorek-Jankowska A, Lamparczyk H (June 1996). "Simultaneous determination of spironolactone and its metabolites in human plasma". Journal of Pharmaceutical and Biomedical Analysis. 14 (8–10): 1359–65. doi:10.1016/S0731-7085(96)01767-0. PMID 8818057.
Deinum J, Riksen NP, Lenders JW (October 2015). "Pharmacological treatment of aldosterone excess". Pharmacology & Therapeutics. 154: 120–33. doi:10.1016/j.pharmthera.2015.07.006. PMID 26213109.
Overdiek HW, Merkus FW (November 1986). "Influence of food on the bioavailability of spironolactone". Clinical Pharmacology and Therapeutics. 40 (5): 531–6. doi:10.1038/clpt.1986.219. PMID 3769384. S2CID 32313529.
Melander A, Danielson K, Scherstén B, Thulin T, Wåhlin E (July 1977). "Enhancement by food of canrenone bioavailability from spironolactone". Clinical Pharmacology and Therapeutics. 22 (1): 100–3. doi:10.1002/cpt1977221100. PMID 872489. S2CID 12827850.
Saini-Chohan HK, Hatch GM (March 2009). "Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure". Current Drug Metabolism. 10 (3): 206–19. doi:10.2174/138920009787846314. PMID 19442083.
Al-Hadiya BM, Belal F, Asiri YA, Gubara OA (2002). "Spironolactone". Analytical Profiles of Drug Substances and Excipients. 29: 261–320. doi:10.1016/S1075-6280(02)29009-6. ISBN 978-0-12-260829-2. ISSN 1075-6280.
Rey FO, Valterio C, Locatelli L, Ramelet AA, Felber JP (April 1988). "Lack of endocrine systemic side effects after topical application of spironolactone in man". Journal of Endocrinological Investigation. 11 (4): 273–8. doi:10.1007/BF03350151. PMID 3411088. S2CID 30535049.
Rifka SM, Pita JC, Vigersky RA, Wilson YA, Loriaux DL (February 1978). "Interaction of digitalis and spironolactone with human sex steroid receptors". The Journal of Clinical Endocrinology and Metabolism. 46 (2): 338–44. doi:10.1210/jcem-46-2-338. PMID 86546.
Pugeat MM, Dunn JF, Nisula BC (July 1981). "Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma". The Journal of Clinical Endocrinology and Metabolism. 53 (1): 69–75. doi:10.1210/jcem-53-1-69. PMID 7195405.
Murck H, Büttner M, Kircher T, Konrad C (2014). "Genetic, molecular and clinical determinants for the involvement of aldosterone and its receptors in major depression". Nephron Physiology. 128 (1–2): 17–25. doi:10.1159/000368265. PMID 25376974. S2CID 19905165.
Künzel HE (March 2012). "Psychopathological symptoms in patients with primary hyperaldosteronism--possible pathways". Hormone and Metabolic Research. 44 (3): 202–7. doi:10.1055/s-0032-1301921. PMID 22351473. S2CID 23273751.
Varin F, Tu TM, Benoît F, Villeneuve JP, Théorêt Y (February 1992). "High-performance liquid chromatographic determination of spironolactone and its metabolites in human biological fluids after solid-phase extraction". Journal of Chromatography. 574 (1): 57–64. doi:10.1016/0378-4347(92)80097-A. PMID 1629288.
Simon JA (December 1995). "Micronized progesterone: vaginal and oral uses". Clinical Obstetrics and Gynecology. 38 (4): 902–14. doi:10.1097/00003081-199538040-00024. PMID 8616985.
Hu X, Li S, McMahon EG, Lala DS, Rudolph AE (August 2005). "Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone". Mini Reviews in Medicinal Chemistry. 5 (8): 709–18. doi:10.2174/1389557054553811. PMID 16101407.
Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
Cutler GB, Pita JC, Rifka SM, Menard RH, Sauer MA, Loriaux DL (July 1978). "SC 25152: A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat prostate". The Journal of Clinical Endocrinology and Metabolism. 47 (1): 171–5. doi:10.1210/jcem-47-1-171. PMID 263288.
Hertz R, Tullner WW (November 1958). "Progestational activity of certain steroid-17-spirolactones". Proceedings of the Society for Experimental Biology and Medicine. 99 (2): 451–2. doi:10.3181/00379727-99-24380. PMID 13601900. S2CID 20150966.
Larik FA, Saeed A, Shahzad D, Faisal M, El-Seedi H, Mehfooz H, et al. (February 2017). "Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives". Steroids. 118: 76–92. doi:10.1016/j.steroids.2016.12.010. PMID 28041953. S2CID 7003499.
Kagawa CM, Cella JA, Van Arman CG (November 1957). "Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt". Science. 126 (3281): 1015–6. Bibcode:1957Sci...126.1015K. doi:10.1126/science.126.3281.1015. PMID 13486053.
Liddle GW (November 1957). "Sodium diuresis induced by steroidal antagonists of aldosterone". Science. 126 (3281): 1016–8. Bibcode:1957Sci...126.1016L. doi:10.1126/science.126.3281.1016. PMID 13486054.
Smith WG (1962). "Spironolactone and gynaecomastia". The Lancet. 280 (7261): 886. doi:10.1016/S0140-6736(62)90668-2. ISSN 0140-6736.
Steelman SL, Brooks JR, Morgan ER, Patanelli DJ (October 1969). "Anti-androgenic activity of spironolactone". Steroids. 14 (4): 449–50. doi:10.1016/s0039-128x(69)80007-3. PMID 5344274.
Stewart ME, Pochi PE (April 1978). "Antiandrogens and the skin". International Journal of Dermatology. 17 (3): 167–79. doi:10.1111/j.1365-4362.1978.tb06057.x. PMID 148431. S2CID 43649686.
Neill JD, Johansson ED, Datta JK, Knobil, E (1968). "Endocrinology: Relationship Between the Plasma Levels of Luteinizing Hormone and Progesterone During the Normal Menstrual Cycle". Obstetrical & Gynecological Survey. 23 (3): 271–277. doi:10.1097/00006254-196803000-00006.
Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacology & Therapeutics. 24 (3): 367–400. doi:10.1016/0163-7258(84)90010-X. PMID 6205409.
Ober KP, Hennessy JF (November 1978). "Spironolactone therapy for hirsutism in a hyperandrogenic woman". Annals of Internal Medicine. 89 (5 Pt 1): 643–4. doi:10.7326/0003-4819-89-5-643. PMID 717935.
Boisselle A, Tremblay RR (September 1979). "New therapeutic approach to the hirsute patient". Fertility and Sterility. 32 (3): 276–9. doi:10.1016/s0015-0282(16)44232-9. PMID 488407.
Shapiro G, Evron S (September 1980). "A novel use of spironolactone: treatment of hirsutism". The Journal of Clinical Endocrinology and Metabolism. 51 (3): 429–32. doi:10.1210/jcem-51-3-429. PMID 7410528.
Dahl M, Feldman JL, Goldberg JM, Jaberi A (2006). "Physical Aspects of Transgender Endocrine Therapy". International Journal of Transgenderism. 9 (3–4): 111–134. doi:10.1300/J485v09n03_06. ISSN 1553-2739. S2CID 146232471.
Fisher AD, Maggi M (2015). "Endocrine Treatment of Transsexual Male-to-Female Persons". Management of Gender Dysphoria. Springer. pp. 83–91. doi:10.1007/978-88-470-5696-1_10. ISBN 978-88-470-5695-4.
Matzkin H, Braf Z (January 1991). "Endocrine treatment of benign prostatic hypertrophy: current concepts". Urology. 37 (1): 1–16. doi:10.1016/0090-4295(91)80069-j. PMID 1702565.
Castro JE, Griffiths HJ, Edwards DE (July 1971). "A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy". The British Journal of Surgery. 58 (7): 485–9. doi:10.1002/bjs.1800580703. PMID 4104441. S2CID 27601630.
Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 (Suppl 7): 1929–1936. doi:10.1002/cncr.1980.45.s7.1929. PMID 29603164. S2CID 4492779.
Smith JA (January 1987). "New methods of endocrine management of prostatic cancer". The Journal of Urology. 137 (1): 1–10. doi:10.1016/S0022-5347(17)43855-9. PMID 3540320.
Verma D, Thompson J, Swaminathan S (March 2016). "Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function". Proceedings of the National Academy of Sciences of the United States of America. 113 (13): 3609–14. Bibcode:2016PNAS..113.3609V. doi:10.1073/pnas.1523686113. PMC 4822607. PMID 26976570.
Pelle MT, Crawford GH, James WD (October 2004). "Rosacea: II. Therapy". Journal of the American Academy of Dermatology. 51 (4): 499–512, quiz 513–4. doi:10.1016/j.jaad.2004.03.033. PMID 15389184.
Merticariu A, Marinescu L, Giurcăneanu C (2016). "Rosacea and its comorbidities". Journal of Translational Medicine and Research. 21 (1): 17. doi:10.21614/jtmr-21-1-68 (inactive 9 November 2024). ISSN 2393-4999.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Wollina U (2014). "Nonclassical Treatments". Pathogenesis and Treatment of Acne and Rosacea. Springer. pp. 713–717. doi:10.1007/978-3-540-69375-8_95. ISBN 978-3-540-69374-1.
Spoendlin J, Voegel JJ, Jick SS, Meier CR (October 2013). "Spironolactone may reduce the risk of incident rosacea". The Journal of Investigative Dermatology. 133 (10): 2480–2483. doi:10.1038/jid.2013.186. PMID 23594595.
Wernze H, Herdegen T (April 2014). "Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: An observational case series". Scandinavian Journal of Pain. 5 (2): 63–71. doi:10.1016/j.sjpain.2013.12.003. PMID 29913681. S2CID 49305801.
Kalso E (April 2014). "From patient observation to potential new therapies-Is old spironolactone a new analgesic?". Scandinavian Journal of Pain. 5 (2): 61–62. doi:10.1016/j.sjpain.2014.02.006. PMID 29913669. S2CID 49298333.
McElroy SL, Guerdjikova AI, Mori N, O'Melia AM (October 2012). "Current pharmacotherapy options for bulimia nervosa and binge eating disorder". Expert Opinion on Pharmacotherapy. 13 (14): 2015–26. doi:10.1517/14656566.2012.721781. PMID 22946772. S2CID 1747393.

drugs.com

"Spironolactone Pregnancy and Breastfeeding Warnings". The American Society of Health-System Pharmacists. Archived from the original on 2 December 2015. Retrieved 29 November 2015.
"Spironolactone". The American Society of Health-System Pharmacists. Archived from the original on 16 November 2015. Retrieved 24 October 2015.
"Spironolactone". Archived from the original on 2 December 2016. Retrieved 1 December 2016.

europa.eu

ema.europa.eu

"Qaialdo EPAR". European Medicines Agency (EMA). 25 July 2023. Archived from the original on 27 July 2023. Retrieved 2 August 2023.

ec.europa.eu

"Qaialdo". Union Register of medicinal products. 31 May 2023. Archived from the original on 6 June 2023. Retrieved 6 June 2023.

fda.gov

accessdata.fda.gov

"Drugs@FDA: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA). Archived from the original on 16 November 2016. Retrieved 14 August 2018.

fda.gov

"Aldactazide (spironolactone/hydrochlorothiazide) Tablets". U.S. Food and Drug Administration (FDA). Archived from the original on 10 March 2015. Retrieved 3 March 2014.

fu-berlin.de

refubium.fu-berlin.de

Schultebraucks K (2016). The Role of the Mineralocorticoid Receptor for Cognitive Function, Mood and Social Cognition (PDF) (Dissertation). doi:10.17169/refubium-6940. Archived from the original on 28 December 2018. Retrieved 27 December 2018.

handle.net

hdl.handle.net

Draganov DI, La Du BN (January 2004). "Pharmacogenetics of paraoxonases: a brief review". Naunyn-Schmiedeberg's Archives of Pharmacology. 369 (1): 78–88. doi:10.1007/s00210-003-0833-1. hdl:2027.42/46312. PMID 14579013. S2CID 15825605.
World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
Brown J, Farquhar C, Lee O, Toomath R, Jepson RG (April 2009). "Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne". The Cochrane Database of Systematic Reviews (2): CD000194. doi:10.1002/14651858.CD000194.pub2. hdl:2292/9640. PMID 19370553.
ter Heegde F, De Rijk RH, Vinkers CH (February 2015). "The brain mineralocorticoid receptor and stress resilience". Psychoneuroendocrinology. 52: 92–110. doi:10.1016/j.psyneuen.2014.10.022. hdl:1874/331554. PMID 25459896. S2CID 14297156.

harvard.edu

ui.adsabs.harvard.edu

Colby HD (April 1981). "Chemical suppression of steroidogenesis". Environmental Health Perspectives. 38: 119–27. Bibcode:1981EnvHP..38..119C. doi:10.1289/ehp.8138119. PMC 1568425. PMID 6786868.
Kagawa CM, Cella JA, Van Arman CG (November 1957). "Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt". Science. 126 (3281): 1015–6. Bibcode:1957Sci...126.1015K. doi:10.1126/science.126.3281.1015. PMID 13486053.
Liddle GW (November 1957). "Sodium diuresis induced by steroidal antagonists of aldosterone". Science. 126 (3281): 1016–8. Bibcode:1957Sci...126.1016L. doi:10.1126/science.126.3281.1016. PMID 13486054.
Verma D, Thompson J, Swaminathan S (March 2016). "Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function". Proceedings of the National Academy of Sciences of the United States of America. 113 (13): 3609–14. Bibcode:2016PNAS..113.3609V. doi:10.1073/pnas.1523686113. PMC 4822607. PMID 26976570.

losalt.com

"Advisory Statement" (PDF). Klinge Chemicals / LoSalt. Archived from the original (PDF) on 15 November 2006. Retrieved 15 March 2007.

lshtm.ac.uk

researchonline.lshtm.ac.uk

Sinnott SJ, Tomlinson LA, Root AA, Mathur R, Mansfield KE, Smeeth L, et al. (February 2017). "Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis" (PDF). European Journal of Preventive Cardiology. 24 (3): 228–238. doi:10.1177/2047487316675194. PMID 27856806.

medicines.org.uk

"Aldactone 25 mg Film-Coated TabletsSummary of Product Characteristics (SmPC)". (emc). 3 February 2022. Archived from the original on 6 October 2022. Retrieved 2 August 2023.

medlineplus.gov

"Spironolactone". MedlinePlus. U.S. National Library of Medicine. 2019. Archived from the original on 5 July 2016. Retrieved 31 October 2019.

moderntranshormones.com

Cosgrove B (January 2018). "The Case Against Spironolactone". Modern Trans Hormones. Retrieved 8 July 2024.

nih.gov

pubmed.ncbi.nlm.nih.gov

Sica DA (January 2005). "Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis". Heart Failure Reviews. 10 (1): 23–9. doi:10.1007/s10741-005-2345-1. PMID 15947888. S2CID 21437788.
Maron BA, Leopold JA (September 2008). "Mineralocorticoid receptor antagonists and endothelial function". Current Opinion in Investigational Drugs. 9 (9): 963–9. PMC 2967484. PMID 18729003.
Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A (February 2017). "Spironolactone". Journal of Pain and Symptom Management. 53 (2): 288–292. doi:10.1016/j.jpainsymman.2016.12.320. PMID 28024992.
Takamura N, Maruyama T, Ahmed S, Suenaga A, Otagiri M (April 1997). "Interactions of aldosterone antagonist diuretics with human serum proteins". Pharmaceutical Research. 14 (4): 522–6. doi:10.1023/A:1012168020545. PMID 9144743. S2CID 13227538.
Los LE, Pitzenberger SM, Ramjit HG, Coddington AB, Colby HD (1994). "Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites". Drug Metabolism and Disposition. 22 (6): 903–8. doi:10.1016/S0090-9556(25)08434-X. PMID 7895608.
Draganov DI, La Du BN (January 2004). "Pharmacogenetics of paraoxonases: a brief review". Naunyn-Schmiedeberg's Archives of Pharmacology. 369 (1): 78–88. doi:10.1007/s00210-003-0833-1. hdl:2027.42/46312. PMID 14579013. S2CID 15825605.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. (September 1999). "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators". The New England Journal of Medicine. 341 (10): 709–717. doi:10.1056/NEJM199909023411001. PMID 10471456.
Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, et al. (August 2018). "Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials". Medicine. 97 (35): e11942. doi:10.1097/MD.0000000000011942. PMC 6392615. PMID 30170387.
Friedman AJ (October 2015). "Spironolactone for Adult Female Acne". Cutis. 96 (4): 216–217. PMID 27141564.
Sinnott SJ, Tomlinson LA, Root AA, Mathur R, Mansfield KE, Smeeth L, et al. (February 2017). "Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis" (PDF). European Journal of Preventive Cardiology. 24 (3): 228–238. doi:10.1177/2047487316675194. PMID 27856806.
Liszewski W, Boull C (April 2019). "Lack of evidence for feminization of males exposed to spironolactone in utero: A systematic review". Journal of the American Academy of Dermatology. 80 (4): 1147–1148. doi:10.1016/j.jaad.2018.10.023. PMID 30352280. S2CID 53022388.
Landau E, Amar L (June 2016). "Primary aldosteronism and pregnancy". Ann Endocrinol (Paris). 77 (2): 148–60. doi:10.1016/j.ando.2016.04.009. PMID 27156905.
Deng N, Zhong J, Deng Z, Chen M, Yan L, Li H, et al. (25 July 2024). "Case report: A pregnant woman accidental treated with spironolactone in mid-gestation". Frontiers in Pharmacology. 15: 1404251. doi:10.3389/fphar.2024.1404251. PMC 11306061. PMID 39119600.
Burinkul S, Panyakhamlerd K, Suwan A, Tuntiviriyapun P, Wainipitapong S (July 2021). "Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial". The Journal of Sexual Medicine. 18 (7): 1299–1307. doi:10.1016/j.jsxm.2021.05.003. PMID 34274044.
Sehgal I (2023). "Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations". Frontiers in Endocrinology. 14: 1184024. doi:10.3389/fendo.2023.1184024. PMC 10355117. PMID 37476490.
Prior JC, Vigna YM, Watson D (1989). "Spironolactone with Physiological Female Steroids for Presurgical Therapy of Male-To-Female Transsexualism". Archives of Sexual Behavior. 18 (1): 49–57. doi:10.1007/BF01579291. PMID 2540730.
Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, et al. (November 2012). "Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice". European Heart Journal. 33 (22): 2782–2795. doi:10.1093/eurheartj/ehs257. PMID 22942339.
Berbenetz NM, Mrkobrada M (December 2016). "Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis". BMC Cardiovascular Disorders. 16 (1): 246. doi:10.1186/s12872-016-0425-x. PMC 5134129. PMID 27905877.
Bayoumi E, Lam PH, Dooley DJ, Singh S, Faselis C, Morgan CJ, et al. (January 2019). "Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction". The American Journal of Medicine. 132 (1): 71–80.e1. doi:10.1016/j.amjmed.2018.09.011. PMC 6511886. PMID 30240686.
Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, et al. (August 2018). "Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials". Medicine. 97 (35): e11942. doi:10.1097/md.0000000000011942. PMC 6392615. PMID 30170387.
Tsujimoto T, Kajio H (December 2020). "Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension". Journal of the American Heart Association. 9 (23): e018827. doi:10.1161/JAHA.120.018827. PMC 7763779. PMID 33222584.
Delyani JA (April 2000). "Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology". Kidney International. 57 (4): 1408–1411. doi:10.1046/j.1523-1755.2000.00983.x. PMID 10760075.
Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, et al. (May 2023). "Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial". BMJ. 381: e074349. doi:10.1136/bmj-2022-074349. PMC 10543374. PMID 37192767.
Kow CS, Ramachandram DS, Hasan SS, Thiruchelvam K (May 2025). "Spironolactone for the Treatment of Moderate to Severe Acne in Adult Women: A Systematic Review and Meta-Analysis of Randomised Controlled Trials". The Australasian Journal of Dermatology. 66 (3): 165–168. doi:10.1111/ajd.14428. PMID 39912292.
Hughes BR, Cunliffe WJ (May 1988). "Tolerance of spironolactone". The British Journal of Dermatology. 118 (5): 687–691. doi:10.1111/j.1365-2133.1988.tb02571.x. PMID 2969259. S2CID 208286107.
Loy R, Seibel MM (December 1988). "Evaluation and therapy of polycystic ovarian syndrome". Endocrinology and Metabolism Clinics of North America. 17 (4): 785–813. doi:10.1016/S0889-8529(18)30410-9. PMID 3143568.
Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. (June 2017). "Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure". Journal of the American College of Cardiology. 69 (25): 3042–3051. doi:10.1016/j.jacc.2017.04.042. PMID 28641794.
Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, et al. (January 2017). "Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis". Circulation. Heart Failure. 10 (1): e003529. doi:10.1161/CIRCHEARTFAILURE.116.003529. PMC 5265698. PMID 28087688.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. (October 2013). "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Journal of the American College of Cardiology. 62 (16): e147 – e239. doi:10.1016/j.jacc.2013.05.019. PMID 23747642.
Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, et al. (August 2018). "Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials". Medicine. 97 (35): e11942. doi:10.1097/MD.0000000000011942. PMC 6392615. PMID 30170387.
Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E (December 2018). "Role of spironolactone in the treatment of heart failure with preserved ejection fraction". Annals of Translational Medicine. 6 (23): 461. doi:10.21037/atm.2018.11.16. PMC 6312809. PMID 30603649.
Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N, et al. (August 2012). "Eplerenone is not superior to older and less expensive aldosterone antagonists". The American Journal of Medicine. 125 (8): 817–25. doi:10.1016/j.amjmed.2011.12.018. PMID 22840667.
Elshahat A, Mansour A, Ellabban M, Diaa A, Hassan A, Fawzy A, et al. (September 2024). "Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis". BMC Cardiovascular Disorders. 24 (1): 489. doi:10.1186/s12872-024-04103-7. PMC 11395778. PMID 39271992.
Frankenstein L, Seide S, Täger T, Jensen K, Fröhlich H, Clark AL, et al. (March 2020). "Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials". Heart Failure Reviews. 25 (2): 161–171. doi:10.1007/s10741-019-09832-y. PMID 31364027.
Batterink J, Stabler SN, Tejani AM, Fowkes CT (August 2010). "Spironolactone for hypertension". The Cochrane Database of Systematic Reviews (8): CD008169. doi:10.1002/14651858.CD008169.pub2. PMID 20687095.
Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, Lales G, Mitas C, Doumas M (2018). "Mineralocorticoid Receptor Antagonists in Primary Aldosteronism". Curr Pharm Des. 24 (46): 5508–5516. doi:10.2174/1381612825666190311130138. PMID 30854950. S2CID 73727928.
Forestiero V, Sconfienza E, Mulatero P, Monticone S (May 2022). "Primary aldosteronism in pregnancy". Rev Endocr Metab Disord. 24 (1): 39–48. doi:10.1007/s11154-022-09729-6. PMC 9884655. PMID 35536535. S2CID 248574316.
Riester A, Reincke M (January 2015). "Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy". Eur J Endocrinol. 172 (1): R23–30. doi:10.1530/EJE-14-0444. PMID 25163723. S2CID 43338556.
Araujo-Castro M (October 2020). "Treatment of primary hyperaldosteronism". Med Clin (Barc). 155 (7): 302–308. doi:10.1016/j.medcli.2020.04.029. PMID 32586668. S2CID 225657804.
Zouboulis CC, Degitz K (2004). "Androgen action on human skin -- from basic research to clinical significance". Experimental Dermatology. 13 (Suppl 4): 5–10. doi:10.1111/j.1600-0625.2004.00255.x. PMID 15507105. S2CID 34863608.
Endly DC, Miller RA (August 2017). "Oily Skin: A review of Treatment Options". The Journal of Clinical and Aesthetic Dermatology. 10 (8): 49–55. PMC 5605215. PMID 28979664.
Marks LS (2004). "5alpha-reductase: history and clinical importance". Reviews in Urology. 6 (Suppl 9): S11-21. PMC 1472916. PMID 16985920.
Diamanti-Kandarakis E, Tolis G, Duleba AJ (1995). "Androgens and therapeutic aspects of antiandrogens in women". Journal of the Society for Gynecologic Investigation. 2 (4): 577–92. doi:10.1177/107155769500200401. PMID 9420861. S2CID 32242838.
Katsambas AD, Dessinioti C (2010). "Hormonal therapy for acne: why not as first line therapy? facts and controversies". Clinics in Dermatology. 28 (1): 17–23. doi:10.1016/j.clindermatol.2009.03.006. PMID 20082945.
Kim GK, Del Rosso JQ (March 2012). "Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience". The Journal of Clinical and Aesthetic Dermatology. 5 (3): 37–50. PMC 3315877. PMID 22468178.
Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ (April 2017). "Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review". American Journal of Clinical Dermatology. 18 (2): 169–191. doi:10.1007/s40257-016-0245-x. PMC 5360829. PMID 28155090.
Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, et al. (May 2023). "Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial". BMJ. 381: e074349. doi:10.1136/bmj-2022-074349. PMC 10543374. PMID 37192767. S2CID 258717921.
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. (May 2016). "Guidelines of care for the management of acne vulgaris". Journal of the American Academy of Dermatology. 74 (5): 945–73.e33. doi:10.1016/j.jaad.2015.12.037. PMID 26897386.
Shaw JC (October 1996). "Antiandrogen and hormonal treatment of acne". Dermatologic Clinics. 14 (4): 803–11. doi:10.1016/S0733-8635(05)70405-8. PMID 9238337.
Somani N, Turvy D (July 2014). "Hirsutism: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 247–66. doi:10.1007/s40257-014-0078-4. PMID 24889738. S2CID 45234892.
Rathnayake D, Sinclair R (2010). "Use of spironolactone in dermatology". Skinmed. 8 (6): 328–32, quiz 333. PMID 21413648.
Harfmann KL, Bechtel MA (March 2015). "Hair loss in women". Clinical Obstetrics and Gynecology. 58 (1): 185–99. doi:10.1097/GRF.0000000000000081. PMID 25517757. S2CID 20364810.
Cousen P, Messenger A (May 2010). "Female pattern hair loss in complete androgen insensitivity syndrome". The British Journal of Dermatology. 162 (5): 1135–7. doi:10.1111/j.1365-2133.2010.09661.x. PMID 20128792. S2CID 205259907.
Iswaran TJ, Imai M, Betton GR, Siddall RA (May 1997). "An overview of animal toxicology studies with bicalutamide (ICI 176,334)". The Journal of Toxicological Sciences. 22 (2): 75–88. doi:10.2131/jts.22.2_75. PMID 9198005.
Schmidt JB (1998). "Other antiandrogens". Dermatology. 196 (1): 153–7. doi:10.1159/000017850. PMID 9557251. S2CID 22119267.
Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, et al. (September 2009). "Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline". The Journal of Clinical Endocrinology and Metabolism. 94 (9): 3132–54. doi:10.1210/jc.2009-0345. PMID 19509099.
Prior JC, Vigna YM, Watson D (February 1989). "Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism". Archives of Sexual Behavior. 18 (1): 49–57. doi:10.1007/bf01579291. PMID 2540730. S2CID 22802329.
Cunliffe WJ, Bottomley WW (September 1992). "Antiandrogens and acne. A topical approach?". Archives of Dermatology. 128 (9): 1261–4. doi:10.1001/archderm.1992.01680190117017. PMID 1387779.
Vincenzi C, Trevisi P, Farina P, Stinchi C, Tosti A (November 1993). "Facial contact dermatitis due to spironolactone in an anti-acne cream". Contact Dermatitis. 29 (5): 277–8. doi:10.1111/j.1600-0536.1993.tb03569.x. PMID 8112074. S2CID 19134415.
van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N (April 2015). "Interventions for hirsutism (excluding laser and photoepilation therapy alone)". The Cochrane Database of Systematic Reviews. 2015 (4): CD010334. doi:10.1002/14651858.CD010334.pub2. PMC 6481758. PMID 25918921.
Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, et al. (April 2018). "Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis". The Journal of Clinical Endocrinology and Metabolism. 103 (4): 1258–1264. doi:10.1210/jc.2017-02052. PMID 29522176. S2CID 3783739.
Erem C (2013). "Update on idiopathic hirsutism: diagnosis and treatment". Acta Clinica Belgica. 68 (4): 268–74. doi:10.2143/ACB.3267. PMID 24455796. S2CID 39120534.
Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, et al. (March 2018). "Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial". The Journal of Clinical Endocrinology and Metabolism. 103 (3): 824–838. doi:10.1210/jc.2017-01186. PMID 29211888. S2CID 3784055.
Kamangar F, Shinkai K (October 2012). "Acne in the adult female patient: a practical approach". International Journal of Dermatology. 51 (10): 1162–74. doi:10.1111/j.1365-4632.2012.05519.x. PMID 22994662. S2CID 5777817.
Diamanti-Kandarakis E (September 1999). "Current aspects of antiandrogen therapy in women". Current Pharmaceutical Design. 5 (9): 707–23. doi:10.2174/1381612805666230111201150. PMID 10495361.
Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A (March 2017). "Flutamide-induced hepatotoxicity: ethical and scientific issues". European Review for Medical and Pharmacological Sciences. 21 (1 Suppl): 69–77. PMID 28379593.
Trivedi MK, Shinkai K, Murase JE (March 2017). "A Review of hormone-based therapies to treat adult acne vulgaris in women". International Journal of Women's Dermatology. 3 (1): 44–52. doi:10.1016/j.ijwd.2017.02.018. PMC 5419026. PMID 28492054.
Barros B, Thiboutot D (2017). "Hormonal therapies for acne". Clinics in Dermatology. 35 (2): 168–172. doi:10.1016/j.clindermatol.2016.10.009. PMID 28274354.
Hassoun LA, Chahal DS, Sivamani RK, Larsen LN (June 2016). "The use of hormonal agents in the treatment of acne". Seminars in Cutaneous Medicine and Surgery. 35 (2): 68–73. doi:10.12788/j.sder.2016.027 (inactive 1 November 2024). PMID 27416311.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR (June 2019). "Androgens in women: Hormone-modulating therapies for skin disease". Journal of the American Academy of Dermatology. 80 (6): 1509–1521. doi:10.1016/j.jaad.2018.08.061. PMID 30312645. S2CID 52973096.
van Zuuren EJ, Fedorowicz Z, Schoones J (May 2016). "Interventions for female pattern hair loss". The Cochrane Database of Systematic Reviews. 2016 (5): CD007628. doi:10.1002/14651858.CD007628.pub4. PMC 6457957. PMID 27225981.
Brown J, Farquhar C, Lee O, Toomath R, Jepson RG (April 2009). "Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne". The Cochrane Database of Systematic Reviews (2): CD000194. doi:10.1002/14651858.CD000194.pub2. hdl:2292/9640. PMID 19370553.
Sundar S, Dickinson PD (February 2012). "Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate". BMJ Case Reports. 2012: bcr1120115238. doi:10.1136/bcr.11.2011.5238. PMC 3291010. PMID 22665559.
Randolph JF (December 2018). "Gender-Affirming Hormone Therapy for Transgender Females". Clinical Obstetrics and Gynecology. 61 (4): 705–721. doi:10.1097/GRF.0000000000000396. PMID 30256230.
Kolkhof P, Bärfacker L (July 2017). "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". The Journal of Endocrinology. 234 (1): T125 – T140. doi:10.1530/JOE-16-0600. PMC 5488394. PMID 28634268.
Loriaux DL (November 1976). "Spironolactone and endocrine dysfunction". Annals of Internal Medicine. 85 (5): 630–6. doi:10.7326/0003-4819-85-5-630. PMID 984618.
Secora AM, Shin JI, Qiao Y, Alexander GC, Chang AR, Inker LA, et al. (November 2020). "Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure". Mayo Clinic Proceedings. 95 (11): 2408–2419. doi:10.1016/j.mayocp.2020.03.035. PMC 8005315. PMID 33153631.
Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M (August 2006). "Spironolactone and risk of upper gastrointestinal events: population based case-control study". BMJ. 333 (7563): 330. doi:10.1136/bmj.38883.479549.2F. PMC 1539051. PMID 16840442.
Gulmez SE, Lassen AT, Aalykke C, Dall M, Andries A, Andersen BS, et al. (August 2008). "Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study". Br J Clin Pharmacol. 66 (2): 294–9. doi:10.1111/j.1365-2125.2008.03205.x. PMC 2492928. PMID 18507655.
Wandelt-Freerksen E (July 1977). "[Aldactone in the treatment of sarcoidosis of the lungs (author's transl)]". Zeitschrift für Erkrankungen der Atmungsorgane. 149 (1): 156–9. PMID 607621.
Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. (December 2015). "Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone". International Journal of Cardiology. 200: 25–9. doi:10.1016/j.ijcard.2015.05.127. PMID 26404748.
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. (August 2004). "Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study". The New England Journal of Medicine. 351 (6): 543–51. doi:10.1056/NEJMoa040135. PMID 15295047.
Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, et al. (November 2012). "Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice". European Heart Journal. 33 (22): 2782–95. doi:10.1093/eurheartj/ehs257. PMID 22942339.
Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM (May 2010). "Spironolactone use and renal toxicity: population based longitudinal analysis". BMJ. 340: c1768. doi:10.1136/bmj.c1768. PMID 20483947. S2CID 14815504.
Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, Garg AX, et al. (September 2011). "Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study". BMJ. 343: d5228. doi:10.1136/bmj.d5228. PMC 3171211. PMID 21911446.
Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN (March 2015). "Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone". CMAJ. 187 (4): E138 – E143. doi:10.1503/cmaj.140816. PMC 4347789. PMID 25646289.
Plovanich M, Weng QY, Mostaghimi A (September 2015). "Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne". JAMA Dermatology. 151 (9): 941–4. doi:10.1001/jamadermatol.2015.34. PMID 25796182.
Millington K, Liu E, Chan YM (May 2019). "The Utility of Potassium Monitoring in Gender-Diverse Adolescents Taking Spironolactone". Journal of the Endocrine Society. 3 (5): 1031–1038. doi:10.1210/js.2019-00030. PMC 6497918. PMID 31065620.
Hayes H, Russell R, Haugen A, Nagavally S, Sarvaideo J (October 2022). "The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone". Journal of the Endocrine Society. 6 (11): bvac133. doi:10.1210/jendso/bvac133. PMC 9562816. PMID 36267595.
Conn JJ, Jacobs HS (July 1998). "Managing hirsutism in gynaecological practice". British Journal of Obstetrics and Gynaecology. 105 (7): 687–96. doi:10.1111/j.1471-0528.1998.tb10197.x. PMID 9692407. S2CID 34751086.
Ménard J (March 2004). "The 45-year story of the development of an anti-aldosterone more specific than spironolactone". Molecular and Cellular Endocrinology. 217 (1–2): 45–52. doi:10.1016/j.mce.2003.10.008. PMID 15134800. S2CID 19701784.
Thompson DF, Carter JR (1993). "Drug-induced gynecomastia". Pharmacotherapy. 13 (1): 37–45. doi:10.1002/j.1875-9114.1993.tb02688.x. PMID 8094898. S2CID 30322620.
Eckman A, Dobs A (November 2008). "Drug-induced gynecomastia". Expert Opinion on Drug Safety. 7 (6): 691–702. doi:10.1517/14740330802442382. PMID 18983216. S2CID 72716346.
Mathur R, Braunstein GD (1997). "Gynecomastia: pathomechanisms and treatment strategies". Hormone Research. 48 (3): 95–102. doi:10.1159/000185497. PMID 11546925.
Christy NA, Franks AS, Cross LB (September 2005). "Spironolactone for hirsutism in polycystic ovary syndrome". The Annals of Pharmacotherapy. 39 (9): 1517–21. doi:10.1345/aph.1G025. PMID 16076921. S2CID 45708497.
Spritzer PM, Lisboa KO, Mattiello S, Lhullier F (May 2000). "Spironolactone as a single agent for long-term therapy of hirsute patients". Clinical Endocrinology. 52 (5): 587–94. doi:10.1046/j.1365-2265.2000.00982.x. PMID 10792338. S2CID 40606594.
McMullen GR, Van Herle AJ (December 1993). "Hirsutism and the effectiveness of spironolactone in its management". Journal of Endocrinological Investigation. 16 (11): 925–32. doi:10.1007/BF03348960. PMID 8144871. S2CID 42231952.
Nakajima ST, Brumsted JR, Riddick DH, Gibson M (July 1989). "Absence of progestational activity of oral spironolactone". Fertility and Sterility. 52 (1): 155–8. doi:10.1016/s0015-0282(16)60807-5. PMID 2744183.
Olsson HL, Olsson ML (2020). "The Menstrual Cycle and Risk of Breast Cancer: A Review". Frontiers in Oncology. 10: 21. doi:10.3389/fonc.2020.00021. PMC 6993118. PMID 32038990.
ter Heegde F, De Rijk RH, Vinkers CH (February 2015). "The brain mineralocorticoid receptor and stress resilience". Psychoneuroendocrinology. 52: 92–110. doi:10.1016/j.psyneuen.2014.10.022. hdl:1874/331554. PMID 25459896. S2CID 14297156.
Holsboer F (1999). "The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety". Journal of Psychiatric Research. 33 (3): 181–214. doi:10.1016/S0022-3956(98)90056-5. PMID 10367986.
Baldani DP, Skrgatic L, Ougouag R, Kasum M (February 2018). "The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment". Gynecol Endocrinol. 34 (2): 87–91. doi:10.1080/09513590.2017.1381681. PMID 28944709. S2CID 205631980.
Nakhjavani M, Hamidi S, Esteghamati A, Abbasi M, Nosratian-Jahromi S, Pasalar P (October 2009). "Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism". Br J Clin Pharmacol. 68 (4): 634–7. doi:10.1111/j.1365-2125.2009.03483.x. PMC 2780289. PMID 19843067.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. (June 2019). "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 139 (25): e1082 – e1143. doi:10.1161/CIR.0000000000000625. PMC 7403606. PMID 30586774.
Coleman E, Radix AE, Bouman WP, Brown GR, de Vries AL, Deutsch MB, et al. (August 2022). "Standards of Care for the Health of Transgender and Gender Diverse People, Version 8". International Journal of Transgender Health. 23 (Suppl 1): S1 – S259. doi:10.1080/26895269.2022.2100644. ISSN 2689-5269. PMC 9553112. PMID 36238954.
Godsland IF, Wynn V, Crook D, Miller NE (December 1987). "Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions". American Heart Journal. 114 (6): 1467–1503. doi:10.1016/0002-8703(87)90552-7. PMID 3318361.
Cignarella A, Mioni R, Sabbadin C, Dassie F, Parolin M, Vettor R, et al. (December 2020). "Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS". Int J Mol Sci. 21 (24): 9554. doi:10.3390/ijms21249554. PMC 7765466. PMID 33334002.
Lopes RJ, Lourenço AP, Mascarenhas J, Azevedo A, Bettencourt P (November 2008). "Safety of spironolactone use in ambulatory heart failure patients". Clinical Cardiology. 31 (11): 509–13. doi:10.1002/clc.20284. PMC 6652974. PMID 19006114.
Thai KE, Sinclair RD (August 2001). "Spironolactone-induced hepatitis". The Australasian Journal of Dermatology. 42 (3): 180–2. doi:10.1046/j.1440-0960.2001.00510.x. PMID 11488711. S2CID 12160891.
Aiba M, Suzuki H, Kageyama K, Murai M, Tazaki H, Abe O, et al. (June 1981). "Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa". The American Journal of Pathology. 103 (3): 404–10. PMC 1903848. PMID 7195152.
Garthwaite SM, McMahon EG (March 2004). "The evolution of aldosterone antagonists". Molecular and Cellular Endocrinology. 217 (1–2): 27–31. doi:10.1016/j.mce.2003.10.005. PMID 15134797. S2CID 8499861.
Juvet T, Gourineni VC, Ravi S, Zarich SW (September 2013). "Life-threatening hyperkalemia: a potentially lethal drug combination". Connecticut Medicine. 77 (8): 491–3. PMID 24156179.
Shaw JC (February 1991). "Spironolactone in dermatologic therapy". Journal of the American Academy of Dermatology. 24 (2 Pt 1): 236–43. doi:10.1016/0190-9622(91)70034-Y. PMID 1826112.
Leinung MC, Feustel PJ, Joseph J (2018). "Hormonal Treatment of Transgender Women with Oral Estradiol". Transgender Health. 3 (1): 74–81. doi:10.1089/trgh.2017.0035. PMC 5944393. PMID 29756046.
Armanini D, Andrisani A, Bordin L, Sabbadin C (September 2016). "Spironolactone in the treatment of polycystic ovary syndrome". Expert Opinion on Pharmacotherapy. 17 (13): 1713–5. doi:10.1080/14656566.2016.1215430. PMID 27450358. S2CID 19345088.
Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, et al. (March 2007). "Treatment of polycystic ovary syndrome with spironolactone plus licorice". European Journal of Obstetrics, Gynecology, and Reproductive Biology. 131 (1): 61–67. doi:10.1016/j.ejogrb.2006.10.013. PMID 17113210.
Salassa RM, Mattox VR, Rosevear JW (November 1962). "Inhibition of the "mineralocorticoid" activity of licorice by spironolactone". The Journal of Clinical Endocrinology and Metabolism. 22 (11): 1156–9. doi:10.1210/jcem-22-11-1156. PMID 13991036.
Omar HR, Komarova I, El-Ghonemi M, Fathy A, Rashad R, Abdelmalak HD, et al. (August 2012). "Licorice abuse: time to send a warning message". Therapeutic Advances in Endocrinology and Metabolism. 3 (4): 125–38. doi:10.1177/2042018812454322. PMC 3498851. PMID 23185686.
Lin SH, Yang SS, Chau T, Halperin ML (March 2003). "An unusual cause of hypokalemic paralysis: chronic licorice ingestion". The American Journal of the Medical Sciences. 325 (3): 153–6. doi:10.1097/00000441-200303000-00008. PMID 12640291.
Parthasarathy HK, MacDonald TM (March 2007). "Mineralocorticoid receptor antagonists". Current Hypertension Reports. 9 (1): 45–52. doi:10.1007/s11906-007-0009-3. PMID 17362671. S2CID 2090391.
Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, et al. (April 2010). "Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study". Journal of Psychiatric Research. 44 (6): 339–46. doi:10.1016/j.jpsychires.2009.10.006. PMID 19909979.
Mostalac-Preciado CR, de Gortari P, López-Rubalcava C (September 2011). "Antidepressant-like effects of mineralocorticoid but not glucocorticoid antagonists in the lateral septum: interactions with the serotonergic system". Behavioural Brain Research. 223 (1): 88–98. doi:10.1016/j.bbr.2011.04.008. PMID 21515309. S2CID 26986501.
Agusti G, Bourgeois S, Cartiser N, Fessi H, Le Borgne M, Lomberget T (January 2013). "A safe and practical method for the preparation of 7α-thioether and thioester derivatives of spironolactone". Steroids. 78 (1): 102–7. doi:10.1016/j.steroids.2012.09.005. PMID 23063964. S2CID 8992318.
Tamargo J, Segura J, Ruilope LM (April 2014). "Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents". Expert Opinion on Pharmacotherapy. 15 (5): 605–21. doi:10.1517/14656566.2014.879117. PMID 24456327. S2CID 2338377.
Doggrell SA, Brown L (May 2001). "The spironolactone renaissance". Expert Opinion on Investigational Drugs. 10 (5): 943–54. doi:10.1517/13543784.10.5.943. PMID 11322868. S2CID 39820875.
Tremblay RR (May 1986). "Treatment of hirsutism with spironolactone". Clinics in Endocrinology and Metabolism. 15 (2): 363–71. doi:10.1016/S0300-595X(86)80030-5. PMID 2941190.
Shaw JC (November 1996). "Antiandrogen therapy in dermatology". International Journal of Dermatology. 35 (11): 770–8. doi:10.1111/j.1365-4362.1996.tb02970.x. PMID 8915726. S2CID 39334280.
Colby HD (April 1981). "Chemical suppression of steroidogenesis". Environmental Health Perspectives. 38: 119–27. Bibcode:1981EnvHP..38..119C. doi:10.1289/ehp.8138119. PMC 1568425. PMID 6786868.
Rocca ML, Venturella R, Mocciaro R, Di Cello A, Sacchinelli A, Russo V, et al. (June 2015). "Polycystic ovary syndrome: chemical pharmacotherapy". Expert Opinion on Pharmacotherapy. 16 (9): 1369–93. doi:10.1517/14656566.2015.1047344. PMID 26001184. S2CID 43770017.
Ye P, Yamashita T, Pollock DM, Sasano H, Rainey WE (January 2009). "Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis". Hormone and Metabolic Research. 41 (1): 35–9. doi:10.1055/s-0028-1087188. PMC 4277847. PMID 18819053.
Satoh T, Itoh S, Seki T, Itoh S, Nomura N, Yoshizawa I (October 2002). "On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production". The Journal of Steroid Biochemistry and Molecular Biology. 82 (2–3): 209–16. doi:10.1016/S0960-0760(02)00154-1. PMID 12477487. S2CID 9972497.
Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH (October 1977). "Pathophysiology of spironolactone-induced gynecomastia". Annals of Internal Medicine. 87 (4): 398–403. doi:10.7326/0003-4819-87-4-398. PMID 907238.
Poirier D (March 2003). "Inhibitors of 17 beta-hydroxysteroid dehydrogenases". Current Medicinal Chemistry. 10 (6): 453–77. doi:10.2174/0929867033368222. PMID 12570693.
Poirier D (July 2009). "Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases". Anti-Cancer Agents in Medicinal Chemistry. 9 (6): 642–60. doi:10.2174/187152009788680000. PMID 19601747.
Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M (December 2013). "Spironolactone use and the risk of breast and gynecologic cancers". Cancer Epidemiology. 37 (6): 870–5. doi:10.1016/j.canep.2013.10.004. PMID 24189467.
Soubhye J, Alard IC, van Antwerpen P, Dufrasne F (2015). "Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis". Future Medicinal Chemistry. 7 (11): 1431–56. doi:10.4155/fmc.15.74. PMID 26230882.
Berardelli R, Karamouzis I, D'Angelo V, Zichi C, Fussotto B, Giordano R, et al. (February 2013). "Role of mineralocorticoid receptors on the hypothalamus-pituitary-adrenal axis in humans". Endocrine. 43 (1): 51–8. doi:10.1007/s12020-012-9750-8. PMID 22836869. S2CID 34916537.
Otte C, Moritz S, Yassouridis A, Koop M, Madrischewski AM, Wiedemann K, et al. (January 2007). "Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition". Neuropsychopharmacology. 32 (1): 232–8. doi:10.1038/sj.npp.1301217. PMID 17035932. S2CID 10624783.
Hinkelmann K, Hellmann-Regen J, Wingenfeld K, Kuehl LK, Mews M, Fleischer J, et al. (November 2016). "Mineralocorticoid receptor function in depressed patients and healthy individuals". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 71: 183–8. doi:10.1016/j.pnpbp.2016.08.003. PMID 27519144. S2CID 4775178.
Abshagen U, Spörl S, L'age M (February 1978). "Non-interaction of spironolactone medication and cortisol metabolism in man". Klinische Wochenschrift. 56 (3): 135–8. doi:10.1007/BF01478568. PMID 628197. S2CID 30885047.
Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, et al. (November 2010). "Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure". American Heart Journal. 160 (5): 915–21. doi:10.1016/j.ahj.2010.04.024. PMID 21095280.
Kliewer SA, Goodwin B, Willson TM (October 2002). "The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism". Endocrine Reviews. 23 (5): 687–702. doi:10.1210/er.2001-0038. PMID 12372848.
Sabbadin C, Andrisani A, Zermiani M, Donà G, Bordin L, Ragazzi E, et al. (September 2016). "Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI". Journal of Endocrinological Investigation. 39 (9): 1015–21. doi:10.1007/s40618-016-0466-0. PMID 27072668. S2CID 34201900.
Delyani JA (April 2000). "Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology". Kidney International. 57 (4): 1408–11. doi:10.1046/j.1523-1755.2000.00983.x. PMID 10760075.
Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (September 1998). "The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions". The Journal of Clinical Investigation. 102 (5): 1016–23. doi:10.1172/JCI3703. PMC 508967. PMID 9727070.
Karim A (1978). "Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability". Drug Metabolism Reviews. 8 (1): 151–88. doi:10.3109/03602537808993782. PMID 363379.
Beermann B (1984). "Aspects on pharmacokinetics of some diuretics". Acta Pharmacologica et Toxicologica. 54 (Suppl 1): 17–29. doi:10.1111/j.1600-0773.1984.tb03626.x. PMID 6369882.
Overdiek HW, Merkus FW (1987). "The metabolism and biopharmaceutics of spironolactone in man". Reviews on Drug Metabolism and Drug Interactions. 5 (4): 273–302. doi:10.1515/DMDI.1987.5.4.273. PMID 3333882. S2CID 29482256.
Brater DC (November 2011). "Update in diuretic therapy: clinical pharmacology". Seminars in Nephrology. 31 (6): 483–94. doi:10.1016/j.semnephrol.2011.09.003. PMID 22099505.
Kolkhof P, Borden SA (March 2012). "Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics". Molecular and Cellular Endocrinology. 350 (2): 310–7. doi:10.1016/j.mce.2011.06.025. PMID 21771637. S2CID 36894459.
Yang J, Young MJ (April 2016). "Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences". Current Opinion in Pharmacology. 27: 78–85. doi:10.1016/j.coph.2016.02.005. PMID 26939027.
Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B (2017). "Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside". Heart Failure. Handbook of Experimental Pharmacology. Vol. 243. Springer. pp. 271–305. doi:10.1007/164_2016_76. ISBN 978-3-319-59658-7. PMID 27830348.
Jankowski A, Skorek-Jankowska A, Lamparczyk H (June 1996). "Simultaneous determination of spironolactone and its metabolites in human plasma". Journal of Pharmaceutical and Biomedical Analysis. 14 (8–10): 1359–65. doi:10.1016/S0731-7085(96)01767-0. PMID 8818057.
Deinum J, Riksen NP, Lenders JW (October 2015). "Pharmacological treatment of aldosterone excess". Pharmacology & Therapeutics. 154: 120–33. doi:10.1016/j.pharmthera.2015.07.006. PMID 26213109.
Overdiek HW, Merkus FW (November 1986). "Influence of food on the bioavailability of spironolactone". Clinical Pharmacology and Therapeutics. 40 (5): 531–6. doi:10.1038/clpt.1986.219. PMID 3769384. S2CID 32313529.
Melander A, Danielson K, Scherstén B, Thulin T, Wåhlin E (July 1977). "Enhancement by food of canrenone bioavailability from spironolactone". Clinical Pharmacology and Therapeutics. 22 (1): 100–3. doi:10.1002/cpt1977221100. PMID 872489. S2CID 12827850.
Saini-Chohan HK, Hatch GM (March 2009). "Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure". Current Drug Metabolism. 10 (3): 206–19. doi:10.2174/138920009787846314. PMID 19442083.
Rey FO, Valterio C, Locatelli L, Ramelet AA, Felber JP (April 1988). "Lack of endocrine systemic side effects after topical application of spironolactone in man". Journal of Endocrinological Investigation. 11 (4): 273–8. doi:10.1007/BF03350151. PMID 3411088. S2CID 30535049.
Rifka SM, Pita JC, Vigersky RA, Wilson YA, Loriaux DL (February 1978). "Interaction of digitalis and spironolactone with human sex steroid receptors". The Journal of Clinical Endocrinology and Metabolism. 46 (2): 338–44. doi:10.1210/jcem-46-2-338. PMID 86546.
Pugeat MM, Dunn JF, Nisula BC (July 1981). "Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma". The Journal of Clinical Endocrinology and Metabolism. 53 (1): 69–75. doi:10.1210/jcem-53-1-69. PMID 7195405.
Kaulhausen H, Rohner HG, Siedek M, Lafosse M, Breuer H (February 1980). "[Binding capacity of sex hormone binding globulin and corticosteroid-binding globulin in serum of male patients with liver cirrhosis (author's transl)]". Journal of Clinical Chemistry and Clinical Biochemistry (in German). 18 (2): 137–43. PMID 7189544.
Murck H, Büttner M, Kircher T, Konrad C (2014). "Genetic, molecular and clinical determinants for the involvement of aldosterone and its receptors in major depression". Nephron Physiology. 128 (1–2): 17–25. doi:10.1159/000368265. PMID 25376974. S2CID 19905165.
Künzel HE (March 2012). "Psychopathological symptoms in patients with primary hyperaldosteronism--possible pathways". Hormone and Metabolic Research. 44 (3): 202–7. doi:10.1055/s-0032-1301921. PMID 22351473. S2CID 23273751.
Varin F, Tu TM, Benoît F, Villeneuve JP, Théorêt Y (February 1992). "High-performance liquid chromatographic determination of spironolactone and its metabolites in human biological fluids after solid-phase extraction". Journal of Chromatography. 574 (1): 57–64. doi:10.1016/0378-4347(92)80097-A. PMID 1629288.
Simon JA (December 1995). "Micronized progesterone: vaginal and oral uses". Clinical Obstetrics and Gynecology. 38 (4): 902–14. doi:10.1097/00003081-199538040-00024. PMID 8616985.
Hu X, Li S, McMahon EG, Lala DS, Rudolph AE (August 2005). "Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone". Mini Reviews in Medicinal Chemistry. 5 (8): 709–18. doi:10.2174/1389557054553811. PMID 16101407.
Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
Cutler GB, Pita JC, Rifka SM, Menard RH, Sauer MA, Loriaux DL (July 1978). "SC 25152: A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat prostate". The Journal of Clinical Endocrinology and Metabolism. 47 (1): 171–5. doi:10.1210/jcem-47-1-171. PMID 263288.
Hertz R, Tullner WW (November 1958). "Progestational activity of certain steroid-17-spirolactones". Proceedings of the Society for Experimental Biology and Medicine. 99 (2): 451–2. doi:10.3181/00379727-99-24380. PMID 13601900. S2CID 20150966.
Larik FA, Saeed A, Shahzad D, Faisal M, El-Seedi H, Mehfooz H, et al. (February 2017). "Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives". Steroids. 118: 76–92. doi:10.1016/j.steroids.2016.12.010. PMID 28041953. S2CID 7003499.
Kagawa CM, Cella JA, Van Arman CG (November 1957). "Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt". Science. 126 (3281): 1015–6. Bibcode:1957Sci...126.1015K. doi:10.1126/science.126.3281.1015. PMID 13486053.
Liddle GW (November 1957). "Sodium diuresis induced by steroidal antagonists of aldosterone". Science. 126 (3281): 1016–8. Bibcode:1957Sci...126.1016L. doi:10.1126/science.126.3281.1016. PMID 13486054.
Steelman SL, Brooks JR, Morgan ER, Patanelli DJ (October 1969). "Anti-androgenic activity of spironolactone". Steroids. 14 (4): 449–50. doi:10.1016/s0039-128x(69)80007-3. PMID 5344274.
Stewart ME, Pochi PE (April 1978). "Antiandrogens and the skin". International Journal of Dermatology. 17 (3): 167–79. doi:10.1111/j.1365-4362.1978.tb06057.x. PMID 148431. S2CID 43649686.
Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacology & Therapeutics. 24 (3): 367–400. doi:10.1016/0163-7258(84)90010-X. PMID 6205409.
Ober KP, Hennessy JF (November 1978). "Spironolactone therapy for hirsutism in a hyperandrogenic woman". Annals of Internal Medicine. 89 (5 Pt 1): 643–4. doi:10.7326/0003-4819-89-5-643. PMID 717935.
Boisselle A, Tremblay RR (September 1979). "New therapeutic approach to the hirsute patient". Fertility and Sterility. 32 (3): 276–9. doi:10.1016/s0015-0282(16)44232-9. PMID 488407.
Shapiro G, Evron S (September 1980). "A novel use of spironolactone: treatment of hirsutism". The Journal of Clinical Endocrinology and Metabolism. 51 (3): 429–32. doi:10.1210/jcem-51-3-429. PMID 7410528.
Matzkin H, Braf Z (January 1991). "Endocrine treatment of benign prostatic hypertrophy: current concepts". Urology. 37 (1): 1–16. doi:10.1016/0090-4295(91)80069-j. PMID 1702565.
Castro JE, Griffiths HJ, Edwards DE (July 1971). "A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy". The British Journal of Surgery. 58 (7): 485–9. doi:10.1002/bjs.1800580703. PMID 4104441. S2CID 27601630.
Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 (Suppl 7): 1929–1936. doi:10.1002/cncr.1980.45.s7.1929. PMID 29603164. S2CID 4492779.
Smith JA (January 1987). "New methods of endocrine management of prostatic cancer". The Journal of Urology. 137 (1): 1–10. doi:10.1016/S0022-5347(17)43855-9. PMID 3540320.
Verma D, Thompson J, Swaminathan S (March 2016). "Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function". Proceedings of the National Academy of Sciences of the United States of America. 113 (13): 3609–14. Bibcode:2016PNAS..113.3609V. doi:10.1073/pnas.1523686113. PMC 4822607. PMID 26976570.
Pelle MT, Crawford GH, James WD (October 2004). "Rosacea: II. Therapy". Journal of the American Academy of Dermatology. 51 (4): 499–512, quiz 513–4. doi:10.1016/j.jaad.2004.03.033. PMID 15389184.
Spoendlin J, Voegel JJ, Jick SS, Meier CR (October 2013). "Spironolactone may reduce the risk of incident rosacea". The Journal of Investigative Dermatology. 133 (10): 2480–2483. doi:10.1038/jid.2013.186. PMID 23594595.
Wernze H, Herdegen T (April 2014). "Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: An observational case series". Scandinavian Journal of Pain. 5 (2): 63–71. doi:10.1016/j.sjpain.2013.12.003. PMID 29913681. S2CID 49305801.
Kalso E (April 2014). "From patient observation to potential new therapies-Is old spironolactone a new analgesic?". Scandinavian Journal of Pain. 5 (2): 61–62. doi:10.1016/j.sjpain.2014.02.006. PMID 29913669. S2CID 49298333.
McElroy SL, Guerdjikova AI, Mori N, O'Melia AM (October 2012). "Current pharmacotherapy options for bulimia nervosa and binge eating disorder". Expert Opinion on Pharmacotherapy. 13 (14): 2015–26. doi:10.1517/14656566.2012.721781. PMID 22946772. S2CID 1747393.

ncbi.nlm.nih.gov

Maron BA, Leopold JA (September 2008). "Mineralocorticoid receptor antagonists and endothelial function". Current Opinion in Investigational Drugs. 9 (9): 963–9. PMC 2967484. PMID 18729003.
Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, et al. (August 2018). "Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials". Medicine. 97 (35): e11942. doi:10.1097/MD.0000000000011942. PMC 6392615. PMID 30170387.
Deng N, Zhong J, Deng Z, Chen M, Yan L, Li H, et al. (25 July 2024). "Case report: A pregnant woman accidental treated with spironolactone in mid-gestation". Frontiers in Pharmacology. 15: 1404251. doi:10.3389/fphar.2024.1404251. PMC 11306061. PMID 39119600.
Sehgal I (2023). "Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations". Frontiers in Endocrinology. 14: 1184024. doi:10.3389/fendo.2023.1184024. PMC 10355117. PMID 37476490.
Berbenetz NM, Mrkobrada M (December 2016). "Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis". BMC Cardiovascular Disorders. 16 (1): 246. doi:10.1186/s12872-016-0425-x. PMC 5134129. PMID 27905877.
Bayoumi E, Lam PH, Dooley DJ, Singh S, Faselis C, Morgan CJ, et al. (January 2019). "Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction". The American Journal of Medicine. 132 (1): 71–80.e1. doi:10.1016/j.amjmed.2018.09.011. PMC 6511886. PMID 30240686.
Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, et al. (August 2018). "Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials". Medicine. 97 (35): e11942. doi:10.1097/md.0000000000011942. PMC 6392615. PMID 30170387.
Tsujimoto T, Kajio H (December 2020). "Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension". Journal of the American Heart Association. 9 (23): e018827. doi:10.1161/JAHA.120.018827. PMC 7763779. PMID 33222584.
Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, et al. (May 2023). "Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial". BMJ. 381: e074349. doi:10.1136/bmj-2022-074349. PMC 10543374. PMID 37192767.
Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, et al. (January 2017). "Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis". Circulation. Heart Failure. 10 (1): e003529. doi:10.1161/CIRCHEARTFAILURE.116.003529. PMC 5265698. PMID 28087688.
Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, et al. (August 2018). "Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials". Medicine. 97 (35): e11942. doi:10.1097/MD.0000000000011942. PMC 6392615. PMID 30170387.
Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E (December 2018). "Role of spironolactone in the treatment of heart failure with preserved ejection fraction". Annals of Translational Medicine. 6 (23): 461. doi:10.21037/atm.2018.11.16. PMC 6312809. PMID 30603649.
Elshahat A, Mansour A, Ellabban M, Diaa A, Hassan A, Fawzy A, et al. (September 2024). "Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis". BMC Cardiovascular Disorders. 24 (1): 489. doi:10.1186/s12872-024-04103-7. PMC 11395778. PMID 39271992.
Forestiero V, Sconfienza E, Mulatero P, Monticone S (May 2022). "Primary aldosteronism in pregnancy". Rev Endocr Metab Disord. 24 (1): 39–48. doi:10.1007/s11154-022-09729-6. PMC 9884655. PMID 35536535. S2CID 248574316.
Endly DC, Miller RA (August 2017). "Oily Skin: A review of Treatment Options". The Journal of Clinical and Aesthetic Dermatology. 10 (8): 49–55. PMC 5605215. PMID 28979664.
Marks LS (2004). "5alpha-reductase: history and clinical importance". Reviews in Urology. 6 (Suppl 9): S11-21. PMC 1472916. PMID 16985920.
Kim GK, Del Rosso JQ (March 2012). "Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience". The Journal of Clinical and Aesthetic Dermatology. 5 (3): 37–50. PMC 3315877. PMID 22468178.
Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ (April 2017). "Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review". American Journal of Clinical Dermatology. 18 (2): 169–191. doi:10.1007/s40257-016-0245-x. PMC 5360829. PMID 28155090.
Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, et al. (May 2023). "Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial". BMJ. 381: e074349. doi:10.1136/bmj-2022-074349. PMC 10543374. PMID 37192767. S2CID 258717921.
van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N (April 2015). "Interventions for hirsutism (excluding laser and photoepilation therapy alone)". The Cochrane Database of Systematic Reviews. 2015 (4): CD010334. doi:10.1002/14651858.CD010334.pub2. PMC 6481758. PMID 25918921.
Trivedi MK, Shinkai K, Murase JE (March 2017). "A Review of hormone-based therapies to treat adult acne vulgaris in women". International Journal of Women's Dermatology. 3 (1): 44–52. doi:10.1016/j.ijwd.2017.02.018. PMC 5419026. PMID 28492054.
van Zuuren EJ, Fedorowicz Z, Schoones J (May 2016). "Interventions for female pattern hair loss". The Cochrane Database of Systematic Reviews. 2016 (5): CD007628. doi:10.1002/14651858.CD007628.pub4. PMC 6457957. PMID 27225981.
Sundar S, Dickinson PD (February 2012). "Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate". BMJ Case Reports. 2012: bcr1120115238. doi:10.1136/bcr.11.2011.5238. PMC 3291010. PMID 22665559.
Kolkhof P, Bärfacker L (July 2017). "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". The Journal of Endocrinology. 234 (1): T125 – T140. doi:10.1530/JOE-16-0600. PMC 5488394. PMID 28634268.
Secora AM, Shin JI, Qiao Y, Alexander GC, Chang AR, Inker LA, et al. (November 2020). "Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure". Mayo Clinic Proceedings. 95 (11): 2408–2419. doi:10.1016/j.mayocp.2020.03.035. PMC 8005315. PMID 33153631.
Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M (August 2006). "Spironolactone and risk of upper gastrointestinal events: population based case-control study". BMJ. 333 (7563): 330. doi:10.1136/bmj.38883.479549.2F. PMC 1539051. PMID 16840442.
Gulmez SE, Lassen AT, Aalykke C, Dall M, Andries A, Andersen BS, et al. (August 2008). "Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study". Br J Clin Pharmacol. 66 (2): 294–9. doi:10.1111/j.1365-2125.2008.03205.x. PMC 2492928. PMID 18507655.
Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, Garg AX, et al. (September 2011). "Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study". BMJ. 343: d5228. doi:10.1136/bmj.d5228. PMC 3171211. PMID 21911446.
Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN (March 2015). "Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone". CMAJ. 187 (4): E138 – E143. doi:10.1503/cmaj.140816. PMC 4347789. PMID 25646289.
Millington K, Liu E, Chan YM (May 2019). "The Utility of Potassium Monitoring in Gender-Diverse Adolescents Taking Spironolactone". Journal of the Endocrine Society. 3 (5): 1031–1038. doi:10.1210/js.2019-00030. PMC 6497918. PMID 31065620.
Hayes H, Russell R, Haugen A, Nagavally S, Sarvaideo J (October 2022). "The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone". Journal of the Endocrine Society. 6 (11): bvac133. doi:10.1210/jendso/bvac133. PMC 9562816. PMID 36267595.
Olsson HL, Olsson ML (2020). "The Menstrual Cycle and Risk of Breast Cancer: A Review". Frontiers in Oncology. 10: 21. doi:10.3389/fonc.2020.00021. PMC 6993118. PMID 32038990.
Nakhjavani M, Hamidi S, Esteghamati A, Abbasi M, Nosratian-Jahromi S, Pasalar P (October 2009). "Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism". Br J Clin Pharmacol. 68 (4): 634–7. doi:10.1111/j.1365-2125.2009.03483.x. PMC 2780289. PMID 19843067.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. (June 2019). "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 139 (25): e1082 – e1143. doi:10.1161/CIR.0000000000000625. PMC 7403606. PMID 30586774.
Coleman E, Radix AE, Bouman WP, Brown GR, de Vries AL, Deutsch MB, et al. (August 2022). "Standards of Care for the Health of Transgender and Gender Diverse People, Version 8". International Journal of Transgender Health. 23 (Suppl 1): S1 – S259. doi:10.1080/26895269.2022.2100644. ISSN 2689-5269. PMC 9553112. PMID 36238954.
Cignarella A, Mioni R, Sabbadin C, Dassie F, Parolin M, Vettor R, et al. (December 2020). "Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS". Int J Mol Sci. 21 (24): 9554. doi:10.3390/ijms21249554. PMC 7765466. PMID 33334002.
Lopes RJ, Lourenço AP, Mascarenhas J, Azevedo A, Bettencourt P (November 2008). "Safety of spironolactone use in ambulatory heart failure patients". Clinical Cardiology. 31 (11): 509–13. doi:10.1002/clc.20284. PMC 6652974. PMID 19006114.
Aiba M, Suzuki H, Kageyama K, Murai M, Tazaki H, Abe O, et al. (June 1981). "Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa". The American Journal of Pathology. 103 (3): 404–10. PMC 1903848. PMID 7195152.
Leinung MC, Feustel PJ, Joseph J (2018). "Hormonal Treatment of Transgender Women with Oral Estradiol". Transgender Health. 3 (1): 74–81. doi:10.1089/trgh.2017.0035. PMC 5944393. PMID 29756046.
Omar HR, Komarova I, El-Ghonemi M, Fathy A, Rashad R, Abdelmalak HD, et al. (August 2012). "Licorice abuse: time to send a warning message". Therapeutic Advances in Endocrinology and Metabolism. 3 (4): 125–38. doi:10.1177/2042018812454322. PMC 3498851. PMID 23185686.
Colby HD (April 1981). "Chemical suppression of steroidogenesis". Environmental Health Perspectives. 38: 119–27. Bibcode:1981EnvHP..38..119C. doi:10.1289/ehp.8138119. PMC 1568425. PMID 6786868.
Ye P, Yamashita T, Pollock DM, Sasano H, Rainey WE (January 2009). "Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis". Hormone and Metabolic Research. 41 (1): 35–9. doi:10.1055/s-0028-1087188. PMC 4277847. PMID 18819053.
Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (September 1998). "The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions". The Journal of Clinical Investigation. 102 (5): 1016–23. doi:10.1172/JCI3703. PMC 508967. PMID 9727070.
Verma D, Thompson J, Swaminathan S (March 2016). "Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function". Proceedings of the National Academy of Sciences of the United States of America. 113 (13): 3609–14. Bibcode:2016PNAS..113.3609V. doi:10.1073/pnas.1523686113. PMC 4822607. PMID 26976570.

dailymed.nlm.nih.gov

"Aldactone- spironolactone tablet, film coated". DailyMed. 29 November 2018. Archived from the original on 10 September 2015. Retrieved 1 January 2020.

pubchem.ncbi.nlm.nih.gov

"Spironolactone". Archived from the original on 30 June 2016. Retrieved 4 July 2017.

semanticscholar.org

api.semanticscholar.org

Sica DA (January 2005). "Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis". Heart Failure Reviews. 10 (1): 23–9. doi:10.1007/s10741-005-2345-1. PMID 15947888. S2CID 21437788.
Takamura N, Maruyama T, Ahmed S, Suenaga A, Otagiri M (April 1997). "Interactions of aldosterone antagonist diuretics with human serum proteins". Pharmaceutical Research. 14 (4): 522–6. doi:10.1023/A:1012168020545. PMID 9144743. S2CID 13227538.
Draganov DI, La Du BN (January 2004). "Pharmacogenetics of paraoxonases: a brief review". Naunyn-Schmiedeberg's Archives of Pharmacology. 369 (1): 78–88. doi:10.1007/s00210-003-0833-1. hdl:2027.42/46312. PMID 14579013. S2CID 15825605.
Liszewski W, Boull C (April 2019). "Lack of evidence for feminization of males exposed to spironolactone in utero: A systematic review". Journal of the American Academy of Dermatology. 80 (4): 1147–1148. doi:10.1016/j.jaad.2018.10.023. PMID 30352280. S2CID 53022388.
Hughes BR, Cunliffe WJ (May 1988). "Tolerance of spironolactone". The British Journal of Dermatology. 118 (5): 687–691. doi:10.1111/j.1365-2133.1988.tb02571.x. PMID 2969259. S2CID 208286107.
Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, Lales G, Mitas C, Doumas M (2018). "Mineralocorticoid Receptor Antagonists in Primary Aldosteronism". Curr Pharm Des. 24 (46): 5508–5516. doi:10.2174/1381612825666190311130138. PMID 30854950. S2CID 73727928.
Forestiero V, Sconfienza E, Mulatero P, Monticone S (May 2022). "Primary aldosteronism in pregnancy". Rev Endocr Metab Disord. 24 (1): 39–48. doi:10.1007/s11154-022-09729-6. PMC 9884655. PMID 35536535. S2CID 248574316.
Riester A, Reincke M (January 2015). "Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy". Eur J Endocrinol. 172 (1): R23–30. doi:10.1530/EJE-14-0444. PMID 25163723. S2CID 43338556.
Araujo-Castro M (October 2020). "Treatment of primary hyperaldosteronism". Med Clin (Barc). 155 (7): 302–308. doi:10.1016/j.medcli.2020.04.029. PMID 32586668. S2CID 225657804.
Zouboulis CC, Degitz K (2004). "Androgen action on human skin -- from basic research to clinical significance". Experimental Dermatology. 13 (Suppl 4): 5–10. doi:10.1111/j.1600-0625.2004.00255.x. PMID 15507105. S2CID 34863608.
Diamanti-Kandarakis E, Tolis G, Duleba AJ (1995). "Androgens and therapeutic aspects of antiandrogens in women". Journal of the Society for Gynecologic Investigation. 2 (4): 577–92. doi:10.1177/107155769500200401. PMID 9420861. S2CID 32242838.
Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, et al. (May 2023). "Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial". BMJ. 381: e074349. doi:10.1136/bmj-2022-074349. PMC 10543374. PMID 37192767. S2CID 258717921.
Somani N, Turvy D (July 2014). "Hirsutism: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 247–66. doi:10.1007/s40257-014-0078-4. PMID 24889738. S2CID 45234892.
Harfmann KL, Bechtel MA (March 2015). "Hair loss in women". Clinical Obstetrics and Gynecology. 58 (1): 185–99. doi:10.1097/GRF.0000000000000081. PMID 25517757. S2CID 20364810.
Cousen P, Messenger A (May 2010). "Female pattern hair loss in complete androgen insensitivity syndrome". The British Journal of Dermatology. 162 (5): 1135–7. doi:10.1111/j.1365-2133.2010.09661.x. PMID 20128792. S2CID 205259907.
Schmidt JB (1998). "Other antiandrogens". Dermatology. 196 (1): 153–7. doi:10.1159/000017850. PMID 9557251. S2CID 22119267.
Prior JC, Vigna YM, Watson D (February 1989). "Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism". Archives of Sexual Behavior. 18 (1): 49–57. doi:10.1007/bf01579291. PMID 2540730. S2CID 22802329.
Vincenzi C, Trevisi P, Farina P, Stinchi C, Tosti A (November 1993). "Facial contact dermatitis due to spironolactone in an anti-acne cream". Contact Dermatitis. 29 (5): 277–8. doi:10.1111/j.1600-0536.1993.tb03569.x. PMID 8112074. S2CID 19134415.
Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, et al. (April 2018). "Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis". The Journal of Clinical Endocrinology and Metabolism. 103 (4): 1258–1264. doi:10.1210/jc.2017-02052. PMID 29522176. S2CID 3783739.
Erem C (2013). "Update on idiopathic hirsutism: diagnosis and treatment". Acta Clinica Belgica. 68 (4): 268–74. doi:10.2143/ACB.3267. PMID 24455796. S2CID 39120534.
Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, et al. (March 2018). "Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial". The Journal of Clinical Endocrinology and Metabolism. 103 (3): 824–838. doi:10.1210/jc.2017-01186. PMID 29211888. S2CID 3784055.
Kamangar F, Shinkai K (October 2012). "Acne in the adult female patient: a practical approach". International Journal of Dermatology. 51 (10): 1162–74. doi:10.1111/j.1365-4632.2012.05519.x. PMID 22994662. S2CID 5777817.
Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR (June 2019). "Androgens in women: Hormone-modulating therapies for skin disease". Journal of the American Academy of Dermatology. 80 (6): 1509–1521. doi:10.1016/j.jaad.2018.08.061. PMID 30312645. S2CID 52973096.
Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM (May 2010). "Spironolactone use and renal toxicity: population based longitudinal analysis". BMJ. 340: c1768. doi:10.1136/bmj.c1768. PMID 20483947. S2CID 14815504.
Conn JJ, Jacobs HS (July 1998). "Managing hirsutism in gynaecological practice". British Journal of Obstetrics and Gynaecology. 105 (7): 687–96. doi:10.1111/j.1471-0528.1998.tb10197.x. PMID 9692407. S2CID 34751086.
Ménard J (March 2004). "The 45-year story of the development of an anti-aldosterone more specific than spironolactone". Molecular and Cellular Endocrinology. 217 (1–2): 45–52. doi:10.1016/j.mce.2003.10.008. PMID 15134800. S2CID 19701784.
Thompson DF, Carter JR (1993). "Drug-induced gynecomastia". Pharmacotherapy. 13 (1): 37–45. doi:10.1002/j.1875-9114.1993.tb02688.x. PMID 8094898. S2CID 30322620.
Eckman A, Dobs A (November 2008). "Drug-induced gynecomastia". Expert Opinion on Drug Safety. 7 (6): 691–702. doi:10.1517/14740330802442382. PMID 18983216. S2CID 72716346.
Christy NA, Franks AS, Cross LB (September 2005). "Spironolactone for hirsutism in polycystic ovary syndrome". The Annals of Pharmacotherapy. 39 (9): 1517–21. doi:10.1345/aph.1G025. PMID 16076921. S2CID 45708497.
Spritzer PM, Lisboa KO, Mattiello S, Lhullier F (May 2000). "Spironolactone as a single agent for long-term therapy of hirsute patients". Clinical Endocrinology. 52 (5): 587–94. doi:10.1046/j.1365-2265.2000.00982.x. PMID 10792338. S2CID 40606594.
McMullen GR, Van Herle AJ (December 1993). "Hirsutism and the effectiveness of spironolactone in its management". Journal of Endocrinological Investigation. 16 (11): 925–32. doi:10.1007/BF03348960. PMID 8144871. S2CID 42231952.
ter Heegde F, De Rijk RH, Vinkers CH (February 2015). "The brain mineralocorticoid receptor and stress resilience". Psychoneuroendocrinology. 52: 92–110. doi:10.1016/j.psyneuen.2014.10.022. hdl:1874/331554. PMID 25459896. S2CID 14297156.
Baldani DP, Skrgatic L, Ougouag R, Kasum M (February 2018). "The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment". Gynecol Endocrinol. 34 (2): 87–91. doi:10.1080/09513590.2017.1381681. PMID 28944709. S2CID 205631980.
Thai KE, Sinclair RD (August 2001). "Spironolactone-induced hepatitis". The Australasian Journal of Dermatology. 42 (3): 180–2. doi:10.1046/j.1440-0960.2001.00510.x. PMID 11488711. S2CID 12160891.
Garthwaite SM, McMahon EG (March 2004). "The evolution of aldosterone antagonists". Molecular and Cellular Endocrinology. 217 (1–2): 27–31. doi:10.1016/j.mce.2003.10.005. PMID 15134797. S2CID 8499861.
Armanini D, Andrisani A, Bordin L, Sabbadin C (September 2016). "Spironolactone in the treatment of polycystic ovary syndrome". Expert Opinion on Pharmacotherapy. 17 (13): 1713–5. doi:10.1080/14656566.2016.1215430. PMID 27450358. S2CID 19345088.
Parthasarathy HK, MacDonald TM (March 2007). "Mineralocorticoid receptor antagonists". Current Hypertension Reports. 9 (1): 45–52. doi:10.1007/s11906-007-0009-3. PMID 17362671. S2CID 2090391.
Mostalac-Preciado CR, de Gortari P, López-Rubalcava C (September 2011). "Antidepressant-like effects of mineralocorticoid but not glucocorticoid antagonists in the lateral septum: interactions with the serotonergic system". Behavioural Brain Research. 223 (1): 88–98. doi:10.1016/j.bbr.2011.04.008. PMID 21515309. S2CID 26986501.
Agusti G, Bourgeois S, Cartiser N, Fessi H, Le Borgne M, Lomberget T (January 2013). "A safe and practical method for the preparation of 7α-thioether and thioester derivatives of spironolactone". Steroids. 78 (1): 102–7. doi:10.1016/j.steroids.2012.09.005. PMID 23063964. S2CID 8992318.
Tamargo J, Segura J, Ruilope LM (April 2014). "Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents". Expert Opinion on Pharmacotherapy. 15 (5): 605–21. doi:10.1517/14656566.2014.879117. PMID 24456327. S2CID 2338377.
Doggrell SA, Brown L (May 2001). "The spironolactone renaissance". Expert Opinion on Investigational Drugs. 10 (5): 943–54. doi:10.1517/13543784.10.5.943. PMID 11322868. S2CID 39820875.
Shaw JC (November 1996). "Antiandrogen therapy in dermatology". International Journal of Dermatology. 35 (11): 770–8. doi:10.1111/j.1365-4362.1996.tb02970.x. PMID 8915726. S2CID 39334280.
Rocca ML, Venturella R, Mocciaro R, Di Cello A, Sacchinelli A, Russo V, et al. (June 2015). "Polycystic ovary syndrome: chemical pharmacotherapy". Expert Opinion on Pharmacotherapy. 16 (9): 1369–93. doi:10.1517/14656566.2015.1047344. PMID 26001184. S2CID 43770017.
Satoh T, Itoh S, Seki T, Itoh S, Nomura N, Yoshizawa I (October 2002). "On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production". The Journal of Steroid Biochemistry and Molecular Biology. 82 (2–3): 209–16. doi:10.1016/S0960-0760(02)00154-1. PMID 12477487. S2CID 9972497.
Berardelli R, Karamouzis I, D'Angelo V, Zichi C, Fussotto B, Giordano R, et al. (February 2013). "Role of mineralocorticoid receptors on the hypothalamus-pituitary-adrenal axis in humans". Endocrine. 43 (1): 51–8. doi:10.1007/s12020-012-9750-8. PMID 22836869. S2CID 34916537.
Otte C, Moritz S, Yassouridis A, Koop M, Madrischewski AM, Wiedemann K, et al. (January 2007). "Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition". Neuropsychopharmacology. 32 (1): 232–8. doi:10.1038/sj.npp.1301217. PMID 17035932. S2CID 10624783.
Hinkelmann K, Hellmann-Regen J, Wingenfeld K, Kuehl LK, Mews M, Fleischer J, et al. (November 2016). "Mineralocorticoid receptor function in depressed patients and healthy individuals". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 71: 183–8. doi:10.1016/j.pnpbp.2016.08.003. PMID 27519144. S2CID 4775178.
Abshagen U, Spörl S, L'age M (February 1978). "Non-interaction of spironolactone medication and cortisol metabolism in man". Klinische Wochenschrift. 56 (3): 135–8. doi:10.1007/BF01478568. PMID 628197. S2CID 30885047.
Sabbadin C, Andrisani A, Zermiani M, Donà G, Bordin L, Ragazzi E, et al. (September 2016). "Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI". Journal of Endocrinological Investigation. 39 (9): 1015–21. doi:10.1007/s40618-016-0466-0. PMID 27072668. S2CID 34201900.
Overdiek HW, Merkus FW (1987). "The metabolism and biopharmaceutics of spironolactone in man". Reviews on Drug Metabolism and Drug Interactions. 5 (4): 273–302. doi:10.1515/DMDI.1987.5.4.273. PMID 3333882. S2CID 29482256.
Kolkhof P, Borden SA (March 2012). "Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics". Molecular and Cellular Endocrinology. 350 (2): 310–7. doi:10.1016/j.mce.2011.06.025. PMID 21771637. S2CID 36894459.
Overdiek HW, Merkus FW (November 1986). "Influence of food on the bioavailability of spironolactone". Clinical Pharmacology and Therapeutics. 40 (5): 531–6. doi:10.1038/clpt.1986.219. PMID 3769384. S2CID 32313529.
Melander A, Danielson K, Scherstén B, Thulin T, Wåhlin E (July 1977). "Enhancement by food of canrenone bioavailability from spironolactone". Clinical Pharmacology and Therapeutics. 22 (1): 100–3. doi:10.1002/cpt1977221100. PMID 872489. S2CID 12827850.
Rey FO, Valterio C, Locatelli L, Ramelet AA, Felber JP (April 1988). "Lack of endocrine systemic side effects after topical application of spironolactone in man". Journal of Endocrinological Investigation. 11 (4): 273–8. doi:10.1007/BF03350151. PMID 3411088. S2CID 30535049.
Murck H, Büttner M, Kircher T, Konrad C (2014). "Genetic, molecular and clinical determinants for the involvement of aldosterone and its receptors in major depression". Nephron Physiology. 128 (1–2): 17–25. doi:10.1159/000368265. PMID 25376974. S2CID 19905165.
Künzel HE (March 2012). "Psychopathological symptoms in patients with primary hyperaldosteronism--possible pathways". Hormone and Metabolic Research. 44 (3): 202–7. doi:10.1055/s-0032-1301921. PMID 22351473. S2CID 23273751.
Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
Hertz R, Tullner WW (November 1958). "Progestational activity of certain steroid-17-spirolactones". Proceedings of the Society for Experimental Biology and Medicine. 99 (2): 451–2. doi:10.3181/00379727-99-24380. PMID 13601900. S2CID 20150966.
Larik FA, Saeed A, Shahzad D, Faisal M, El-Seedi H, Mehfooz H, et al. (February 2017). "Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives". Steroids. 118: 76–92. doi:10.1016/j.steroids.2016.12.010. PMID 28041953. S2CID 7003499.
Stewart ME, Pochi PE (April 1978). "Antiandrogens and the skin". International Journal of Dermatology. 17 (3): 167–79. doi:10.1111/j.1365-4362.1978.tb06057.x. PMID 148431. S2CID 43649686.
Dahl M, Feldman JL, Goldberg JM, Jaberi A (2006). "Physical Aspects of Transgender Endocrine Therapy". International Journal of Transgenderism. 9 (3–4): 111–134. doi:10.1300/J485v09n03_06. ISSN 1553-2739. S2CID 146232471.
Castro JE, Griffiths HJ, Edwards DE (July 1971). "A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy". The British Journal of Surgery. 58 (7): 485–9. doi:10.1002/bjs.1800580703. PMID 4104441. S2CID 27601630.
Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 (Suppl 7): 1929–1936. doi:10.1002/cncr.1980.45.s7.1929. PMID 29603164. S2CID 4492779.
Wernze H, Herdegen T (April 2014). "Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: An observational case series". Scandinavian Journal of Pain. 5 (2): 63–71. doi:10.1016/j.sjpain.2013.12.003. PMID 29913681. S2CID 49305801.
Kalso E (April 2014). "From patient observation to potential new therapies-Is old spironolactone a new analgesic?". Scandinavian Journal of Pain. 5 (2): 61–62. doi:10.1016/j.sjpain.2014.02.006. PMID 29913669. S2CID 49298333.
McElroy SL, Guerdjikova AI, Mori N, O'Melia AM (October 2012). "Current pharmacotherapy options for bulimia nervosa and binge eating disorder". Expert Opinion on Pharmacotherapy. 13 (14): 2015–26. doi:10.1517/14656566.2012.721781. PMID 22946772. S2CID 1747393.

sgo-iasgo.com

Merticariu A, Marinescu L, Giurcăneanu C (2016). "Rosacea and its comorbidities". Journal of Translational Medicine and Research. 21 (1): 17. doi:10.21614/jtmr-21-1-68 (inactive 9 November 2024). ISSN 2393-4999.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)

web.archive.org

Loughlin KR, Generali JA (2006). The Guide to Off-label Prescription Drugs: New Uses for FDA-approved Prescription Drugs. Simon and Schuster. pp. 131–. ISBN 978-0-7432-8667-1. Archived from the original on 7 October 2022. Retrieved 6 November 2016.
Clark MA, Harvey RA, Finkel R, Rey JA, Whalen K (15 December 2011). Pharmacology. Lippincott Williams & Wilkins. pp. 286, 337. ISBN 978-1-4511-1314-3. Archived from the original on 7 October 2022. Retrieved 6 November 2016.
"Spironolactone Pregnancy and Breastfeeding Warnings". The American Society of Health-System Pharmacists. Archived from the original on 2 December 2015. Retrieved 29 November 2015.
"Spironolactone". The American Society of Health-System Pharmacists. Archived from the original on 16 November 2015. Retrieved 24 October 2015.
Farid NR, Diamanti-Kandarakis E (27 February 2009). Diagnosis and Management of Polycystic Ovary Syndrome. Springer Science & Business Media. pp. 235–. ISBN 978-0-387-09718-3. Archived from the original on 7 October 2022. Retrieved 6 November 2016.
"Aldactone 25 mg Film-Coated TabletsSummary of Product Characteristics (SmPC)". (emc). 3 February 2022. Archived from the original on 6 October 2022. Retrieved 2 August 2023.
"Aldactone- spironolactone tablet, film coated". DailyMed. 29 November 2018. Archived from the original on 10 September 2015. Retrieved 1 January 2020.
"Qaialdo EPAR". European Medicines Agency (EMA). 25 July 2023. Archived from the original on 27 July 2023. Retrieved 2 August 2023.
"Qaialdo". Union Register of medicinal products. 31 May 2023. Archived from the original on 6 June 2023. Retrieved 6 June 2023.
McDonagh TA, Gardner RS, Clark AL, Dargie H (14 July 2011). Oxford Textbook of Heart Failure. OUP Oxford. pp. 403–. ISBN 978-0-19-957772-9. Archived from the original on 27 March 2017.
Parkinson A (2001). Biotransformation of Xenobiotics. McGraw-Hill. pp. 137–138, 169, 171, 180, 195, 208. Archived from the original on 7 October 2022. Retrieved 12 August 2018.
Klaassen CD (11 December 2007). Casarett & Doull's Toxicology: The Basic Science of Poisons, Seventh Edition. McGraw Hill Professional. p. 173. ISBN 978-0-07-159351-9. Archived from the original on 7 October 2022. Retrieved 12 August 2018.
Black HR, Elliott W (28 December 2006). Hypertension: A Companion to Braunwald's Heart Disease. Elsevier Health Sciences. pp. 295–. ISBN 978-1-4377-1078-6. Archived from the original on 7 October 2022. Retrieved 12 August 2018.
The World Professional Association for Transgender Health (WPATH) (2011). "Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People" (PDF). Archived from the original (PDF) on 23 May 2012. Retrieved 27 May 2012.
Deedwania PC (30 January 2014). Drug & Device Selection in Heart Failure. JP Medical Ltd. pp. 47–. ISBN 978-93-5090-723-8. Archived from the original on 7 October 2022. Retrieved 5 July 2017.
Ottow E, Weinmann H (9 July 2008). Nuclear Receptors As Drug Targets. John Wiley & Sons. p. 410. ISBN 978-3-527-62330-3. Archived from the original on 21 June 2013. Retrieved 28 May 2012.
Wermuth CG (24 July 2008). The Practice of Medicinal Chemistry. Academic Press. p. 34. ISBN 978-0-12-374194-3. Archived from the original on 21 June 2013. Retrieved 27 May 2012.
Sittig M (1988). Pharmaceutical Manufacturing Encyclopedia. William Andrew. p. 1385. ISBN 978-0-8155-1144-1. Archived from the original on 20 June 2013. Retrieved 27 May 2012.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
Ronco C, Bellomo R, Kellum JA, Ricci Z (14 December 2017). Critical Care Nephrology E-Book. Elsevier Health Sciences. pp. 371–. ISBN 978-0-323-51199-5. Archived from the original on 7 October 2022. Retrieved 17 August 2018.
Preedy VR (1 January 2012). Handbook of Hair in Health and Disease. Springer Science & Business Media. pp. 132–. ISBN 978-90-8686-728-8. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Shalita AR, Del Rosso JQ, Webster G (21 March 2011). Acne Vulgaris. CRC Press. pp. 33–. ISBN 978-1-61631-009-7. Archived from the original on 9 December 2016.
Zouboulis CC, Katsambas AD, Kligman AM (28 July 2014). Pathogenesis and Treatment of Acne and Rosacea. Springer. pp. 121–. ISBN 978-3-540-69375-8. Archived from the original on 10 December 2016.
Sloane E (2002). Biology of Women. Cengage Learning. pp. 160–. ISBN 978-0-7668-1142-3. Archived from the original on 7 October 2022. Retrieved 5 July 2017.
Hanno PM, Guzzo TJ, Malkowicz SB, Wein AJ (26 January 2014). Penn Clinical Manual of Urology E-Book: Expert Consult - Online. Elsevier Health Sciences. pp. 782–. ISBN 978-0-323-24466-4. Archived from the original on 7 October 2022. Retrieved 5 July 2017.
Harper C (1 August 2007). Intersex. Berg. pp. 123–. ISBN 978-1-84788-339-1. Archived from the original on 7 October 2022. Retrieved 5 July 2017.
Blume-Peytavi U, Whiting DA, Trüeb RM (26 June 2008). Hair Growth and Disorders. Springer Science & Business Media. pp. 161–162. ISBN 978-3-540-46911-7. Archived from the original on 7 October 2022. Retrieved 16 July 2017.
Smith RE (4 April 2013). Medicinal Chemistry – Fusion of Traditional and Western Medicine. Bentham Science Publishers. pp. 306–. ISBN 978-1-60805-149-6. Archived from the original on 29 May 2016.
Ostrzenski A (2002). Gynecology: Integrating Conventional, Complementary, and Natural Alternative Therapy. Lippincott Williams & Wilkins. pp. 86–. ISBN 978-0-7817-2761-7. Archived from the original on 6 October 2022. Retrieved 5 July 2017.
Shelley WB, Shelley ED (2001). Advanced Dermatologic Therapy II. W. B. Saunders. ISBN 978-0-7216-8258-7. Archived from the original on 6 October 2022. Retrieved 2 January 2019.
Balen A, Franks S, Homburg R, Kehoe S (October 2010). Current Management of Polycystic Ovary Syndrome. Cambridge University Press. pp. 132–. ISBN 978-1-906985-41-7. Archived from the original on 6 October 2022. Retrieved 2 January 2019.
Muller NF, Dessing RP (19 June 1998). European Drug Index: European Drug Registrations (Fourth ed.). CRC Press. pp. 44–. ISBN 978-3-7692-2114-5. Archived from the original on 7 October 2022. Retrieved 29 November 2017.
Lee M, Desai A (2007). Gibaldi's Drug Delivery Systems in Pharmaceutical Care. ASHP. pp. 312–. ISBN 978-1-58528-136-7. Archived from the original on 7 October 2022. Retrieved 1 December 2016.
Niazi SK (19 April 2016). Handbook of Pharmaceutical Manufacturing Formulations, Second Edition: Volume One, Compressed Solid Products. CRC Press. pp. 470–. ISBN 978-1-4200-8117-6. Archived from the original on 7 October 2022. Retrieved 1 December 2016.
Wakelin SH, Maibach HI, Archer CB (1 June 2002). Systemic Drug Treatment in Dermatology: A Handbook. CRC Press. pp. 32, 35. ISBN 978-1-84076-013-2. Archived from the original on 7 October 2022. Retrieved 1 December 2016.
"Drugs@FDA: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA). Archived from the original on 16 November 2016. Retrieved 14 August 2018.
"Spironolactone". Archived from the original on 2 December 2016. Retrieved 1 December 2016.
Goldsmith D, Covic A, Spaak J (12 November 2014). Cardio-Renal Clinical Challenges. Springer. pp. 167–. ISBN 978-3-319-09162-4. Archived from the original on 7 October 2022. Retrieved 17 August 2018.
Seldin DW, Giebisch GH (23 September 1997). Diuretic Agents: Clinical Physiology and Pharmacology. Academic Press. pp. 630–632. ISBN 978-0-08-053046-8. Archived from the original on 4 July 2014.
Aronson JK (2 March 2009). Meyler's Side Effects of Cardiovascular Drugs. Elsevier. pp. 253–258. ISBN 978-0-08-093289-7. Archived from the original on 7 October 2022. Retrieved 16 October 2016.
Carrell DT, Peterson CM (23 March 2010). Reproductive Endocrinology and Infertility: Integrating Modern Clinical and Laboratory Practice. Springer Science & Business Media. pp. 162–. ISBN 978-1-4419-1436-1. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
"Spironolactone". MedlinePlus. U.S. National Library of Medicine. 2019. Archived from the original on 5 July 2016. Retrieved 31 October 2019.
Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 708, 777, 1087, 1196. ISBN 978-0-7817-1750-2. Archived from the original on 6 October 2022. Retrieved 6 May 2018.
Tsioufis C, Schmieder R, Mancia G (15 August 2016). Interventional Therapies for Secondary and Essential Hypertension. Springer. p. 44. ISBN 978-3-319-34141-5. Archived from the original on 7 October 2022. Retrieved 16 October 2016.
McInnes GT (2008). Clinical Pharmacology and Therapeutics of Hypertension. Elsevier. p. 125. ISBN 978-0-444-51757-9. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Wilcox CS (22 August 2008). Therapy in Nephrology and Hypertension E-Book: A Companion to Brenner & Rector's The Kidney. Elsevier Health Sciences. pp. 607–. ISBN 978-1-4377-1124-0. Archived from the original on 7 October 2022. Retrieved 17 August 2018.
Jemec G, Revuz J, Leyden JJ (24 November 2006). Hidradenitis Suppurativa. Springer Science & Business Media. pp. 125–. ISBN 978-3-540-33101-8. Archived from the original on 7 October 2022. Retrieved 15 August 2018.
Schultebraucks K (2016). The Role of the Mineralocorticoid Receptor for Cognitive Function, Mood and Social Cognition (PDF) (Dissertation). doi:10.17169/refubium-6940. Archived from the original on 28 December 2018. Retrieved 27 December 2018.
Basson R, Prior JC (1998). "Hormonal Therapy of Gender Dysphoria: The Male-to-Female Transsexual". In Denny D (ed.). Current Concepts in Transgender Identity. Taylor & Francis. pp. 277–296. doi:10.4324/9780203775134. ISBN 978-1-134-82110-5. Archived from the original on 7 October 2022. Retrieved 2 January 2019.
"Aldactazide (spironolactone/hydrochlorothiazide) Tablets". U.S. Food and Drug Administration (FDA). Archived from the original on 10 March 2015. Retrieved 3 March 2014.
Ainsworth SB (10 November 2014). Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. pp. 486–. ISBN 978-1-118-81959-3. Archived from the original on 8 September 2017.
Little B (29 September 2006). Drugs and Pregnancy: A Handbook. CRC Press. pp. 63–. ISBN 978-0-340-80917-4. Archived from the original on 8 September 2017.
Rubin PC, Ramsey M (30 April 2008). Prescribing in Pregnancy. John Wiley & Sons. pp. 83–. ISBN 978-0-470-69555-5. Archived from the original on 8 September 2017.
Briggs GG, Freeman RK, Yaffe SJ (2011). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. pp. 1349–. ISBN 978-1-60831-708-0. Archived from the original on 8 September 2017.
Gleicher N, Elkayam U, Gleicher N (23 June 1998). Cardiac Problems in Pregnancy: Diagnosis and Management of Maternal and Fetal Heart Disease. John Wiley & Sons. pp. 353–. ISBN 978-0-471-16358-9. Archived from the original on 8 September 2017.
Schaefer C (2001). Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment. Gulf Professional Publishing. pp. 115, 143. ISBN 978-0-444-50763-1. Archived from the original on 8 September 2017.
Upfal J (2006). Australian Drug Guide. Black Inc. pp. 671–. ISBN 978-1-86395-174-6. Archived from the original on 8 September 2017.
"Advisory Statement" (PDF). Klinge Chemicals / LoSalt. Archived from the original (PDF) on 15 November 2006. Retrieved 15 March 2007.
Davis MP (28 May 2009). Opioids in Cancer Pain. OUP Oxford. pp. 222–. ISBN 978-0-19-923664-0. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Wolverton SE (8 March 2007). Comprehensive Dermatologic Drug Therapy. Elsevier Health Sciences. pp. 2677–. ISBN 978-1-4377-2070-9. Archived from the original on 7 October 2022. Retrieved 7 May 2017.
International Agency for Research on Cancer, World Health Organization (2001). Some Thyrotropic Agents. World Health Organization. pp. 325–. ISBN 978-92-832-1279-9. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Ginés P, Arroyo V, Rodés J, Schrier RW (15 April 2008). Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. John Wiley & Sons. pp. 229, 231. ISBN 978-1-4051-4370-7. Archived from the original on 7 October 2022. Retrieved 6 May 2018.
Feldman AM (15 April 2008). Heart Failure: Pharmacologic Management. John Wiley & Sons. pp. 89–103. ISBN 978-1-4051-7253-0. Archived from the original on 7 October 2022. Retrieved 13 August 2018.
Strauss III JF, Barbieri RL (13 September 2013). Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. pp. 237–. ISBN 978-1-4557-2758-2. Archived from the original on 7 October 2022. Retrieved 13 August 2018.
Haff GG, Triplett NT (23 September 2015). Essentials of Strength Training and Conditioning 4th Edition. Human Kinetics. pp. 76–. ISBN 978-1-4925-0162-6. Archived from the original on 7 October 2022. Retrieved 14 August 2018.
Wu JJ (18 October 2012). Comprehensive Dermatologic Drug Therapy E-Book. Elsevier Health Sciences. pp. 364–. ISBN 978-1-4557-3801-4. Archived from the original on 7 October 2022. Retrieved 6 May 2018.
Coelingh Benni HJ, Vemer HM (15 December 1990). Chronic Hyperandrogenic Anovulation. CRC Press. pp. 152–. ISBN 978-1-85070-322-8. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Adams KF (28 October 2014). Pharmacologic Approaches to Heart Failure, An Issue of Heart Failure Clinics, E-Book. Elsevier Health Sciences. pp. 562–. ISBN 978-0-323-32612-4. Archived from the original on 7 October 2022. Retrieved 13 August 2018.
Falcone T, Hurd WW (1 January 2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. pp. 271–. ISBN 978-0-323-03309-1. Archived from the original on 7 October 2022. Retrieved 13 August 2018.
Kuntz E, Kuntz HD (11 March 2009). Hepatology: Textbook and Atlas. Springer Science & Business Media. pp. 312–. ISBN 978-3-540-76839-5. Archived from the original on 7 October 2022. Retrieved 13 August 2018.
Aldosterone. Elsevier Science. 23 January 2019. pp. 11, 46. ISBN 978-0-12-817783-9. Archived from the original on 7 October 2022. Retrieved 20 September 2019.
Bland KI, Copeland III EM (9 September 2009). The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Health Sciences. pp. 161–. ISBN 978-1-4377-1121-9. Archived from the original on 7 October 2022. Retrieved 14 September 2017.
Oxford Textbook of Medicine: Vol. 1. Oxford University Press. 2003. pp. 1–. ISBN 978-0-19-262922-7. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Anzenbacher P, Zanger UM (23 February 2012). Metabolism of Drugs and Other Xenobiotics. John Wiley & Sons. pp. 166, 169. ISBN 978-3-527-64632-6. Archived from the original on 7 October 2022. Retrieved 12 August 2018.
Smith BT, Seaward BL, Smith BT (1 November 2014). Pharmacology for Nurses. Jones & Bartlett Publishers. pp. 169–. ISBN 978-1-4496-8940-7. Archived from the original on 7 October 2022. Retrieved 6 October 2016.
Ortiz de Montellano PR (13 March 2015). Cytochrome P450: Structure, Mechanism, and Biochemistry. Springer. pp. 867–. ISBN 978-3-319-12108-6. Archived from the original on 7 October 2022. Retrieved 12 August 2018.
Brittain HG (26 November 2002). Analytical Profiles of Drug Substances and Excipients. Academic Press. p. 309. ISBN 978-0-12-260829-2. Archived from the original on 21 June 2013. Retrieved 27 May 2012.
Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 1111. ISBN 978-1-4757-2085-3. Archived from the original on 15 February 2017.
"Spironolactone". Archived from the original on 30 June 2016. Retrieved 4 July 2017.
"Spironolactone | C24H32O4S". ChemSpider. Royal Society of Chemistry. Archived from the original on 9 September 2017. Retrieved 4 July 2017.
The British Encyclopaedia of Medical Practice: Medical progress. Butterworth & Company. 1961. p. 302. Archived from the original on 7 October 2022. Retrieved 2 February 2018.
Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1279–1280. ISBN 978-3-13-179275-4. Archived from the original on 7 October 2022. Retrieved 27 December 2016.
Landau R, Achilladelis B, Scriabine A (1999). Pharmaceutical Innovation: Revolutionizing Human Health. Chemical Heritage Foundation. pp. 198–. ISBN 978-0-941901-21-5. Archived from the original on 7 October 2022. Retrieved 27 December 2016.
Jugdutt BI (19 February 2014). Aging and Heart Failure: Mechanisms and Management. Springer Science & Business Media. pp. 175–. ISBN 978-1-4939-0268-2. Archived from the original on 7 October 2022. Retrieved 27 December 2016.
Wermuth CG (2 May 2011). The Practice of Medicinal Chemistry. Academic Press. pp. 34–. ISBN 978-0-08-056877-5. Archived from the original on 21 June 2013.
Shah D, Bhathena RK, Shroff S (2004). The Polycystic Ovary Syndrome. Orient Blackswan. pp. 78–. ISBN 978-81-250-2633-4. Archived from the original on 7 October 2022. Retrieved 4 July 2017.
Hillard PJ (29 March 2013). Practical Pediatric and Adolescent Gynecology. John Wiley & Sons. pp. 371–. ISBN 978-1-118-53857-9. Archived from the original on 7 October 2022. Retrieved 4 July 2017.
Gláz E, Vecsei P (11 January 2017). Aldosterone: International Series of Monographs in Pure and Applied Biology. Elsevier Science. p. 379. ISBN 978-1-4831-5997-3. Archived from the original on 10 October 2022. Retrieved 31 December 2020.
Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261ff. ISBN 978-0-7514-0499-9. Archived from the original on 7 October 2022. Retrieved 1 December 2016.
Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 266–. ISBN 978-1-4612-5476-8. Archived from the original on 7 October 2022. Retrieved 30 July 2017.

worldcat.org

search.worldcat.org

Endou H, Hosoyamada M (1995). "Potassium-Retaining Diuretics: Aldosterone Antagonists". Diuretics. Handbook of Experimental Pharmacology. Vol. 117. Springer. pp. 335–361. doi:10.1007/978-3-642-79565-7_9. ISBN 978-3-642-79567-1. ISSN 0171-2004.
Yasa C, Dural Ö, Bastu E, Uğurlucan FG (2016). "Hirsutism, Acne, and Hair Loss: Management of Hyperandrogenic Cutaneous Manifestations of Polycystic Ovary Syndrome". Gynecology Obstetrics & Reproductive Medicine. 23 (2): 110–119. doi:10.21613/GORM.2016.613. ISSN 1300-4751.
Rabe T, Grunwald K, Feldmann K, Runnebaum B (2009). "Treatment of hyperandrogenism in women". Gynecological Endocrinology. 10 (sup3): 1–44. doi:10.3109/09513599609045658. ISSN 0951-3590.
Coleman E, Radix AE, Bouman WP, Brown GR, de Vries AL, Deutsch MB, et al. (August 2022). "Standards of Care for the Health of Transgender and Gender Diverse People, Version 8". International Journal of Transgender Health. 23 (Suppl 1): S1 – S259. doi:10.1080/26895269.2022.2100644. ISSN 2689-5269. PMC 9553112. PMID 36238954.
Al-Hadiya BM, Belal F, Asiri YA, Gubara OA (2002). "Spironolactone". Analytical Profiles of Drug Substances and Excipients. 29: 261–320. doi:10.1016/S1075-6280(02)29009-6. ISBN 978-0-12-260829-2. ISSN 1075-6280.
Smith WG (1962). "Spironolactone and gynaecomastia". The Lancet. 280 (7261): 886. doi:10.1016/S0140-6736(62)90668-2. ISSN 0140-6736.
Dahl M, Feldman JL, Goldberg JM, Jaberi A (2006). "Physical Aspects of Transgender Endocrine Therapy". International Journal of Transgenderism. 9 (3–4): 111–134. doi:10.1300/J485v09n03_06. ISSN 1553-2739. S2CID 146232471.
Merticariu A, Marinescu L, Giurcăneanu C (2016). "Rosacea and its comorbidities". Journal of Translational Medicine and Research. 21 (1): 17. doi:10.21614/jtmr-21-1-68 (inactive 9 November 2024). ISSN 2393-4999.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)

wpath.org

The World Professional Association for Transgender Health (WPATH) (2011). "Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People" (PDF). Archived from the original (PDF) on 23 May 2012. Retrieved 27 May 2012.